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PREFACE 
 
This thesis is divided into eight chapters, including this one: 
 
Chapter 1: 
This is an introductory chapter that addresses the background, rationale and relevance of the study as 
well as the proposed aim and objectives. The general outline and structure of the thesis concludes this 
chapter. 
 
Chapter 2: 
This chapter provides a comprehensive literature review on HCV and the urgent need for continuous 
research that will facilitate the design, discovery and development of more effective and potent potential 
inhibitors, which address challenges that hinder the efficacy of current market-available anti-HCV 
drugs. This chapter includes the discovery, epidemiology, transmission, life cycle, viral diagnostics, 
pathogenesis, clinical features, viral characteristics (mechanistic and structural), viral/host drug targets, 
specifically the NS5 and NS3 protein and explores the field of covalent inhibition.  
 
Chapter 3: 
This chapter explains computer aided drug design by discussing various molecular dynamic approaches 
and applications. The computational tools and software required to study the comparative inhibitory 
modes of proteins as well as methods to analyse binding affinity are also explained. This chapter 
conceptualizes computer-aided drug design by discussing various molecular modelling and molecular 
dynamic techniques and applications. The computational tools needed to investigate comparative 
enzymatic structural/conformational characteristics as well as methods used to analyse binding affinity 
is elucidated upon. 
 
Chapter 4: (Published work- this chapter is presented in the required format of the journal and 
is the final version of the accepted manuscript) 
This chapter provides an all exclusive “road map” entitled “Road Map for the Structure-Based Design 
of Selective Covalent HCV NS3/4A Protease Inhibitors”. This study provides a comprehensive 
overview from literature and presents technical guidance that may be used to initiate a systematic “road 
map” for the design of selective covalent inhibitors that may assist medicinal chemists and scientists in 
the design and development of optimized potential selective covalent HCV NS3/4A viral protease 
inhibitors.  This article was published in The Protein Journal (impact factor (IF) = 1.133). 
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Chapter 5: (Published work- this chapter is presented in the required format of the journal and 
is the final version of the accepted manuscript)  
This chapter investigates the second objective of the thesis and is titled “Targeting HCV Polymerase: 
A Structural and Dynamic Perspective into the Mechanism of Selective Covalent Inhibition”. This study 
implements an optimised molecular modelling approach to better understand the structural and dynamic 
impact of selective covalent inhibitor binding to HCV NS5B RNA-dependent RNA polymerase 
(RdRp). This article has been published in RSC Advances (IF = 3.049). 
 
Chapter 6: (This chapter is presented in the required format of the journal and is the final 
version of the submitted manuscript)  
This chapter, “Enhanced Pharmacophore-based Virtual Screening Approach in the Discovery of 
Potential Inhibitors of HCV NS3 Helicase”, assesses the third objective of the thesis: To identify 
potential HCV NS3 helicase inhibitors through utilisation of the pharmacophore-based virtual screening 
approach using the chemical scaffold of quercetin as a model. This study implements an enhanced and 
proven screening approach to identify lead compounds that may be potentially used as inhibitors of 
HCV NS3 helicase. This computational “per-residue energy decomposition pharmacophore” virtual 
screening approach will be impetus in initiating the discovery of effective inhibitors of HCV viral 
targets. This article has been submitted. 
 
Chapter 7:  
This is the final chapter that proposes future work and concluding remarks. 
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ABSTRACT 
 
Hepatitis C Virus (HCV) is an escalating global healthcare and economic burden that requires extensive 
intervention to alleviate its control. Over the years, drug design efforts have produced many anti-HCV 
drugs; however, due to drug resistance brought on by numerous genetic variations of the virus and lack 
of specificity and stability, current drugs are rendered ineffective. The situation has been further 
intensified by the absence of a viable vaccine. For these reasons, continuous HCV research is imperative 
for the design and development of promising inhibitors that address the challenges faced by present 
antiviral therapies. Moreover, exposure of previously neglected viral protein targets can offer another 
potentially valuable therapeutic route in drug design research. 
 
Structure-based drug design approaches accentuate the development of small inhibitor molecules that 
interact with therapeutic targets through non-covalent interactions. The unexpected discovery of 
covalent inhibitors and their distinctive nature of instigating complete and irreversible inhibition of 
targets have shifted attention away from the use of non-covalent drugs in antiviral treatment. This has 
led to significant progress in understanding covalent inhibition regarding their underlying mechanism 
of action and in the design of novel covalent inhibitors that work against biological targets. However, 
due to difficulties arising in its application and resultant safety, the pharmaceutical industry were 
reluctant to pursue this strategy. With the use of rational drug design, a novel strategy was then proposed 
known as selective covalent inhibition. Due to the lack of competent protocols and information, little is 
known regarding selective covalent inhibition 
 
 
This study investigates three biological HCV targets, NS3 protease, RNA helicase and NS5B RNA-
dependent RNA polymerase. With constantly evolving viruses like HCV, computational methods 
including molecular modelling and docking, virtual screening and molecular dynamic simulations have 
allowed chemists to screen millions of compounds to filter out potential lead drugs. These in silico 
approaches have allowed Computer-Aided Drug Design as a cost-effective strategy to accelerate the 
process of drug discovery. 
 
The above techniques, with numerous other computational tools were employed in this study to fill the 
gap in HCV drug research by providing insights into the structural and dynamic changes that describe 
the mechanism of selective covalent inhibition and pharmacophoric features that lead to unearthing of 
potential small inhibitor molecules against Hepatitis C.
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The first study (Chapter 4) provides a comprehensive review on HCV NS3/4A protein, current therapies 
and covalent inhibition as well as introduces a technical guideline that provides a systematic approach 
for the design and development of potent, selective HCV inhibitors.   
 
The second study (Chapter 5) provides a comprehensive understanding concerning the implications of 
selective covalent inhibition on the activity of HCV NS5B RNA-dependent RNA polymerase, with 
respect to key components required for viral replication, when bound to a target-specific small inhibitor 
molecule.  
 
The third study (Chapter 6) is preliminary investigation that uses Pharmacophore-based virtual 
screening as an efficient tool for the discovery of improved potential HCV NS3 helicase inhibitors. The 
pharmacophoric features were created based on the highly contributing amino acid residues that bind 
with highest affinity to the weak inhibitor, quercetin. These residues were identified based on free 
energy footprints obtained from molecular dynamic and thermodynamic calculations. Post molecular 
dynamic analysis and appropriate drug-likeness properties of the three top-hit compounds revealed that 
ZINC02495613 could be a more effective potential HCV helicase inhibitor; however, further validation 
steps are still required.  
 
This study offers a comprehensive in silico perspective to fill the gap in rational drug design research 
against HCV, thus providing an insight into the mechanism of selective covalent inhibition, uncovering 
a previously neglected viral target and identifying possible antiviral drugs. To this end, the work 
presented in this report is considered a fundamental platform to advance research toward the design and 
development of novel and selective anti-HCV drugs.  
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CHAPTER 1 
1 Introduction 
 
1.1 Background and Rationale of the Study 
Hepatitis C virus (HCV) is the main cause of hepatic-related diseases throughout the world. 
Approximately 3% of the world’s population is believed to be chronic carriers of the virus (Karoney 
and Sika, 2013). Annually, at least 3 to 4 million individuals contract HCV, mainly through 
contaminated blood transfusions or intravenous drug use involving an infected person (Mohamed et al., 
2015; Thrift, El-Serag and Kanwal, 2017). The HCV infection is categorized into two states: acute and 
chronic. Usually the acute HCV infection is asymptomatic; however, in some cases, patients experience 
jaundice, malaise and slight fatigue (Blackard, 2008; Sagnelli et al., 2014).  Amongst those infected, 
60-80%, which is approximately 130 to 170 million individuals will progress into the chronic state 
(Mohamed et al., 2015). This state of infection is distinguished by the development of hepatic cirrhosis, 
fibrosis and steatohepatitis (El-Zayadi, 2008; Ghany and Jake Liang, 2016; Zeremski et al., 2016). In 
cases of fatality, patients often succumb to the viral infection due to extensive hepatic damage caused 
by hepatocellular carcinoma development or the host’s immune response (Baumert et al., 2017).  
 
There are two principle drug targets of HCV, non-structural protein 3 and 5B RNA-dependent RNA 
polymerase (NS3 and NS5B RdRp, respectively). The NS3 protein is a complex consisting of a serine 
protease, RNA helicase and co-factor, NS4A (Chevaliez and Pawlotsky, 2006; Shunmugam, 
Ramharack and Soliman, 2017). The protease portion of the complex is highly targeted for antiviral 
drug development owing to its vital role in the HCV life cycle. The protease functions by mediating the 
cleavage of precursor proteins for the generation of functional products and facilitating post-
translational processing of structural proteins, required for viral assembly and morphogenesis. The NS3 
RNA helicase is an often-overlooked aspect of the HCV enzyme complex. The helicase is considered 
to be an indispensable component of viral transcription, translation and RNA splicing; however, there 
is an evident lack in literature pertaining to the helicase and its possible role in antiviral drug discovery.  
The second most popular drug target is the NS5B RdRp. The protein is responsible for facilitating  RNA 
genome transcription and subsequent viral replication (Eltahla et al., 2015).   
 
Presently, few  antiviral drugs have been approved for HCV treatment, which targets the NS3 protease, 
such as narlaprevir (Arasappan et al., 2010), telaprevir (Kwong et al., 2011) and combined therapy with 
pegylated interferon-alpha and ribavirin ; and the RdRp, such as sofosbuvir (Bhatia et al., 2014) and 
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dasabuvir (Goldenberg, 2014). However, there is still a pressing need for more effective HCV 
therapeutics. Numerous complications have been encountered, casting a negative stigma on the 
effectiveness of the antiviral drugs. It has been reported that only 50-60% of infected individuals 
positively respond to current HCV therapies (Bowen and Walker, 2005).  Mutations due to the initiative 
of HCV to survive and escape the host immune response has facilitated the emergence of several genetic 
variations, thus giving way to drug resistance. Another serious drawback to current HCV drugs comes 
in the form of undesirable adverse effects, which harshly impacts the well-being of patients with an 
already compromised health status caused by the infection. To date, no preventive HCV vaccine is 
available, thus continual HCV research is an absolute necessity for the development of improved and 
effective antiviral therapies or vaccine against this ruinous disease. The major obstacles in achieving 
this goal is the absence of an appropriate small animal model susceptible to the HCV infection and the 
inability to cultivate HCV in vitro. The only animal that is capable of being infected by HCV is the 
chimpanzee, but due to ethical reasons, endangered species status and high maintenance expenses, its 
use is limited (Saleh, Elhaes and Ibrahim, 2017). These setbacks have prompted a surge in 
computational drug design research efforts for the development of antiviral therapies that selectively 
target HCV viral proteins and explore promising novel drug targets.  
 
Computer-aided drug design (CADD) approaches have extensively contributed  toward the design and 
development of drugs against a wide variety of diseases (Yu and MacKerell, 2017). Computational 
procedures are often utilised to accelerate the discovery  process and direct attention toward compounds 
exhibiting potential antiviral activities, elaborate on protein-drug interactions and provide 
enhancements for eligible compounds (Kore et al., 2012; Das, Saha and Abdul, 2017). The CADD 
strategy in drug discovery can be applied at every stage, from target identification, to optimisation of 
drugs and preclinical investigations (Lu et al. 2012; Huang et al.2010; Song et al. 2009; Anderson 
2003). With diseases like HCV having a global affect, CADD techniques including molecular 
modelling, molecular docking, virtual screening, pharmacophoric moiety identification and molecular 
dynamic simulations allow medicinal and pharmaceutical industries to screen massive quantities of 
compounds to filtrate possible lead drugs that may then be experimentally validated. Implementation 
of CADD vanquishes the notion to estimate or guess with little to no assurance on the accuracy or 
reliability of experimental screening outcomes thus, reducing the time frame of drug discovery.
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In this study, we have utilized major computational techniques to fill the gap in HCV drug design 
research, thus giving insights toward specific drug targets and designing potential selective inhibitors 
against Hepatitis C. 
 
1.2 Aims and Objectives 
The aim of this thesis is to better describe and investigate the main target proteins of HCV and 
subsequently use CADD techniques to investigate potential small-molecule inhibitors against these 
antiviral proteins.  
 
To achieve this, the following objectives were outlined: 
 
1. To introduce a technical guidance for the design and development of potential selective covalent 
inhibitors against HCV NS3/4A by: 
 
1.1 Providing a comprehensive review on the target protein and covalent inhibition. 
 
1.2 Identifying and describing the importance of HCV NS3/4A cysteine159 in selective covalent 
inhibition. 
 
1.3 Creating a technical guideline that provides a systematic approach for the design and 
development of selective covalent inhibitors. 
 
 
2. To better understand the structural and dynamic impact of selective covalent inhibitor binding to 
HCV NS5B RNA-dependent RNA polymerase (RdRp). This may be accomplished by: 
 
2.1 Utilising the crystal structure of HCV RdRp in complex with selective covalent inhibitor, 
compound 47, in a 200ns continuous molecular dynamic simulation.  
 
2.2 Performing post molecular dynamic analyses to investigate the underlying structural and 
dynamic behaviours of the apo RdRp in comparison to compound 47-bound RdRp.
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2.3 Using additional defined parameters to detail the impact of ligand binding on RdRp, in its 
entirety and with respect to key components required for RNA binding and subsequent viral 
replication. 
 
3. To computationally utilize the “Per-residue Energy Decomposition Pharmacophore” virtual 
screening approach to propose potential HCV NS3 helicase inhibitors using the chemical scaffold 
of quercetin as a template. This may be achieved by: 
 
3.1 Performing molecular dynamic simulations to create an ensemble of potent inhibitors in 
complex with HCV NS3 enzyme.  
 
3.2  Quantification of each amino acid residue interaction toward the total binding free energy of 
the system, based on the MM/GBSA method. Thus, creating a pharmacophore-model of the 
complex erected from enzyme-ligand interactions.  
 
3.3 Initiating a search through the Zinc Database for structure-based scaffolds similar to that of 
quercetin, against the NS3 enzyme.  
 
3.4 Measuring the stability of the most favourable ligands as well as binding free energy of each 
complex following molecular dynamic simulation.  
 
3.5 To provide a preliminary investigation that serves as a fundamental platform for future wide-
spectrum screening of potential HCV antiviral drugs against NS3 RNA helicase. 
 
1.3 Novelty and Significance of the Study 
In the past decade, the drug design industry has made significant efforts toward developing a novel 
strategy that allows selective targeting of viruses, a concept known as selective covalent inhibition. This 
strategy employs structure-based approaches to generate small-molecule inhibitors that selectively bind 
to a specific residue of a target protein. The bond formed is designated as covalent and occurs between 
the ligand’s highly reactive warhead and the thiol group of a specific cysteine residue of a target protein. 
The cysteine residue must be conserved across all viral geno and subtypes, and not present in host 
enzymes, thus serving as a perfect candidate for acquiring selectivity. This strategy has been 
demonstrated to be promising to overcome efficacy, potency and selectivity challenges. 
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To date, there are no reported computational studies that provide information concerning this form of 
inhibition related to HCV and its viral proteins. The lack of literature regarding selective covalent 
inhibition, its underlying mechanism of action and the overall impact on structural dynamics of HCV 
prompted us to design a technical guideline or “road map” toward the design and discovery of potential 
selective covalent inhibitors for NS3/4A protease. The guideline was thereafter implemented using the 
NS5B RdRp to provide further insight into selective covalent binding mechanisms of potential antiviral 
drugs in HCV therapy.  The study also reported a previously neglected viral drug target, the RNA 
helicase of the HCV NS3 protein. This was the first account of pharmacophore-based virtual screening 
using quercetin’s chemical scaffolding as a template against the NS3 helicase, thus assisting researchers 
from multidisciplinary fields in designing potential small-molecule inhibitors against the viral protein. 
 
With the use of CADD techniques, a comprehensive in silico perspective is presented to elucidate 
possible structural characteristics that allow for the inhibition of these enzymes as well as amino acid 
residues implicated in activity of the enzyme. Highlighting the binding landscape will aid prospective 
design of selective, potent inhibitors with indispensable pharmacophoric features that will facilitate 
development of targeted and effective small-molecule inhibitors. 
 
To this end, the work presented in this thesis is considered to be a fundamental platform in drug 
development research for the design of more potent and highly selective inhibitors against HCV NS3 
and NS5B proteins with the potential to overcome challenges arising in current HCV therapeutics.
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CHAPTER 2 
 
2. Background on the Hepatitis C Virus 
 
2.1 Introduction 
Hepatitis C Virus (HCV) is a major global health concern and is the main cause of hepatic-related 
diseases such as hepatitis C, cirrhosis, fibrosis and hepatocellular carcinoma (Ghany and Jake 
Liang, 2016). Classified as hepatotropic RNA virus, HCV belongs to Hepacivirus genus and is a 
member of the Flaviviridae family (Lavanchy, 2011; Villani, Bellanti and Serviddio, 2013). The 
World Health Organisation (WHO) revealed that HCV is responsible for affecting approximately 
3% of the world’s population (Lavanchy, 2011; Karoney, Siika and Karoney, 2013; World Health 
Organization, 2018). Every year, 3 to 4 million new HCV infections occur while 170 to 185 
million of infected individuals will progress to the chronic state (Mohamed et al., 2015; Thrift, 
El-Serag and Kanwal, 2017). Currently, there is no HCV vaccine available and to make matters 
worse, compromised health of infected individuals and antiviral resistance facilitated by increased 
presence of viral genetic variants have greatly dampened the success rate of market-available 
drugs (Fonseca-Coronado et al., 2012; Echeverria et al., 2015; Kumthip and Maneekarn, 2015). 
For this reason, constant HCV research is essential for the development of selective antiviral 
therapies or vaccines against this devastating disease. 
 
In this chapter, we provide a comprehensive review of HCV that describes its discovery, 
epidemiology, transmission, life cycle and overall molecular virology. The main focus will be on 
HCV non-structural protein 3 (NS3) and 5B (NS5B) as therapeutic drug targets for the design of 
selective antiviral compounds, which is the key theme of the thesis research. 
 
 
2.2 Discovery and Epidemiology 
The rigorous task of diagnostic assay development for hepatitis A and B virus (HAV and HBV, 
respectively) led Feinstone and co-investigators to discover an additional viral hepatitis of 
unknown origin (Feinstone et al., 1975, 1981). In later years, the unknown viral hepatitis was 
given the name non-A, non-B (NANB) hepatitis as majority of cases involving transfusion-
associated hepatitis were not associated with HAV or HBV infections (Feinstone et al., 1975; 
Bukh, 2016). With the timely development of powerful molecular tools and techniques, the 
etiological agent of transfusion-associated hepatitis was identified. The breakthrough in
9 
 
 identifying the virus occurred in the late 1980s whereby Choo and co-researchers isolated 
antibodies from an individual infected with the unknown viral hepatitis, for the detection of 
specific viral proteins (Choo et al., 1991). Nucleic acid was extracted from the plasma of 
Chimpanzee and experimentally transfected with NANB hepatitis. Thereafter, the infected sample 
was subjected to reverse transcription for complementary DNA (cDNA) generation. Using the 
cDNA, restriction enzyme fragments were inserted into a bacteriophage expression vector. The 
resultant proteins expressed were then analysed by comparing them with the expressed viral 
proteins from the serum of the patient infected with the unknown viral agent (Choo et al., 1991). 
As a result, the causative agent of transfusion-associated NANB hepatitis was successfully 
identified and designated the named, hepatitis C virus (HCV). 
 
Globally, HCV is one of the leading causes of mortality and morbidity (Fedeli et al., 2017). In 
the last ten years, there has been a 2.8% increase in the number of individuals who have tested 
positive for the infectious agent (Petruzziello et al., 2016). Currently, it is estimated that 
approximately 185 million individuals are infected with HCV worldwide (Thrift, El-Serag and 
Kanwal, 2017). The acute stage of HCV infection is relatively slow, asymptomatic and 
spontaneously clears up within six months without medical intervention. Unfortunately, an 
estimated 60-80% of HCV-infected individuals will progress to the chronic state of infection 
(World Health Organization, 2018). The chronic state of HCV infection is commonly linked to 
the development of hepatocellular cancers (Goossens and Hoshida, 2015), cirrhosis (Khullar and 
Firpi, 2015), fibrosis (Sebastiani, Gkouvatsos and Pantopoulos, 2014), hepatic failure and 
ultimately death (Toshikuni, Arisawa and Tsutsumi, 2014). To date, there is no vaccine available 
for use, therefore infected patients heavily rely on therapeutic interventions to treat the disease 
and alleviate symptoms but its only effective in 50% of individuals under treatment.  
 
A high degree of genetic diversity observed in HCV has resulted in the emergence of nine distinct 
genotypes and numerous subtypes of the virus. Despite sharing similar fundamental virology, the 
genotypes differ based on their geographical location and rate of incidence. The geographical 
distribution of HCV is represented in Figure 1. A unique feature of HCV is that the virus exists 
as a populace of non-identical but closely related “quasispecies”, which emerge from mutations 
accruing over time and are not considered different subtypes. The generation of multiple variants 
are due to the error-prone nature of HCV as it lacks adequate proof-reading activities during the 
replication process.   
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Figure 1: Geographical representation of global HCV genotype distribution (Adapted from 
Gower et al., 2014).  
 
 
2.3 Route of Transmission 
The major risks of infection with HCV is through direct percutaneous exposures including sharing 
needles with infected individuals, medical surgery such as organ transplantation from an infected 
donor and receiving infected blood during transfusions (Alter, 2007; Thursz and Fontanet, 2014). 
Individuals at high risk of contracting the virus through blood are those that require continuous 
blood transfusions due to their infliction with diseases such as cancer, haemodialysis-associated 
with chronic renal failure, haemophilia and thalassemia (Moosavy et al., 2017).  Other less 
efficient transmission routes include mucosal exposure to serum or blood during health-care 
associated accidental needlestick injuries (Pozzetto et al., 2014), sexual intercourse (Wuytack et 
al., 2018) or childbirth (Tosone et al., 2014). Perinatal transmission of HCV occurs only in 
instances involving maternal patients with high viral loads or membrane rupturing during 
prolonged labour (Alter, 2007). Another reservoir of HCV transmission is unintentional 
percutaneous exposures that can cause infection through cross-contamination. This involves 
contact with injection-type drug paraphernalia as well as inefficient sterilisation or reuse of 
medical equipment, for example, infusion bags, vials, syringes and needles (Alter, 2007; Kaushik, 
Kapila and Praharaj, 2011).  The contributing risk factors and their associated incidence rate in 
percentage are represented in Figure 2.  
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Figure 2: Risk factors associated with transmission of  HCV (Adapted from Stambouli, 2014). 
 
 
2.4 Molecular Virology 
 
2.4.1 Genome Organisation 
The HCV genome is represented by a positive sense, single-stranded RNA, approximately 9600 
nucleotides in length. The genome is made up of a single open reading frame (ORF), flanked by 
the 5’ and 3’ untranslated regions (5’UTR and 3’UTR, respectively), which is vital for genome 
replication and polyprotein translation (Figure 3)  (Kalinina and Dmitriev, 2015). The ORF 
encodes the polyprotein, which undergoes proteolytic cleavage by cellular and viral proteases to 
generate 10 viral proteins (Takamizawa et al., 1991; Chevaliez and Pawlotsky, 2006; Ashfaq et 
al., 2011; Kalinina and Dmitriev, 2015). The structural proteins  are the core (C), envelope protein 
1 and 2 (E1/E2) and hydrophilic ion channel protein 7 (P7), they are located at the N-terminal of 
the polyprotein The remaining two thirds of the HCV genome is designated as  non-structural 
(NS) proteins: (NS2, NS3, NS4A, NS5A and NS5B) (Villani, Bellanti and Serviddio, 2013; 
Kalinina and Dmitriev, 2015).  
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Figure 3: Schematic representation of hepatitis C virus (HCV) genome organisation of the 
polyprotein and viral particle (Prepared by author). 
 
2.4.2 Viral Proteins 
 
2.4.2.1 Structural 
The first structural protein encoded by the HCV ORF is the core (C), which is responsible for 
nucleocapsid formation and viral morphogenesis (Gawlik and Gallay, 2014). This is a 
multifunctional protein incriminated in the pathogenesis of HCV. Localisation of the C protein 
occurs at the endoplasmic reticulum (ER) membrane, on lipid droplet surfaces and in the 
membranous network. The latter is a structure formed by host factors and viral proteins of HCV.  
The protein is also linked to several other processes such as cell proliferation and death, regulation 
of gene transcription, suppression of host immune response and lipid metabolism interference 
(Moradpour and Penin, 2013; Adler, 2014).  
 
The HCV polyprotein encodes two envelope glycoproteins, E1 and E2. These proteins serve as 
building blocks for the viral envelope and is processed by host peptidases. Expression of both 
glycoproteins are crucial for viral entry and heterodimer formation on the viral envelop (Lavie, 
Goffard and Dubuisson, 2007). The E2 protein encompasses a hyper-variable domain that 
undergoes frequent mutations to sanction the development of antigenic escape variations.  In 
doing so, the host’s immune response can no longer recognise the virus, thus elimination is not 
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possible (Law et al., 2018). Both, E1 an E2 have vital functional roles in viral morphogenesis, 
assembly and entry (Lavie, Goffard and Dubuisson, 2007; Vieyres, Dubuisson and Pietschmann, 
2014).  
 
The p7 protein is identified as hydrophobic peptide with cation-selective ion channel activity 
(Chandler et al., 2012; Madan and Bartenschlager, 2015). The p7 protein is relatively small, 
consisting of 63 amino acids and is partially cleaved by host signal peptidase, from the E2 protein 
(Jones et al., 2007; Madan and Bartenschlager, 2015). Even though the P7 protein is not essential 
for RNA replication, it is however important in viral particle production and subsequent release 
(Lohmann et al., 1999; Jones et al., 2007; Gentzsch et al., 2013).  
 
2.4.2.2 Non-Structural 
The NS2 transmembrane protein that contains an auto-protease that conducts cleavage at the 
NS2/3 juncture (Ma et al., 2011). This cleavage is an essential step in viral replication of HCV 
by permitting downstream processing of the polyprotein. Additionally, the NS2 protein has also 
been known to have an important role in assembly of the virion and it interacts with the envelope 
proteins (Stapleford and Lindenbach, 2011).  
 
The NS3 protein contains two enzymatic functions: helicase and serine protease. The helicase 
activity is actively involved in assembly of the HCV virion and the protease activity is responsible 
for HCV polyprotein cleavage, in order to generate vital proteins required for RNA genome 
replication (McGivern et al., 2015). The co-factor, NS4A aids in membrane association of the 
NS3 protein (Kim, Han and Ahn, 2016).  The NS3 protein is one of the major focuses of this 
work, the structural expression, characteristics, enzymatic activity, and interaction with other host 
and viral factors as well as the efficiency of anti-viral compounds is further elaborated in more 
detail in subsequent sections.  
 
NS4B is a small polytopic membranous protein, whose role is not well understood but it is thought 
to serve as a frame for replicase assemblage (Paul et al., 2011; Kazakov et al., 2015). This protein 
has created quite a challenge in its investigation as it exhibits relatively high hydrophobicity 
(Palomares-Jerez, Nemesio and Villalaín, 2012). The protein is subdivided into three domains: A 
cytosolic C- and N-terminal as well as a central domain. At the N-terminal, the protein fosters 
two amphipathic helices (AH1 and AH2), AH2 is known to contribute to NS4B association to 
cellular membranes (Blight, 2011; Gouttenoire et al., 2014; David et al., 2015). The NS4B protein 
has three main functional features that are perceived to be contributing factors toward initiating 
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the formation of the membranous web. Firstly, NS4B has the ability to form oligomers, which is 
facilitated mainly by C-terminal components and amphipathic helix 2. The second feature is the 
ability of the protein’s amphipathic helix 2 domain to endorse aggregation of lipid vesicles. 
Lastly, the third feature is the ability of the N-terminal to post-translationally translocate into the 
ER lumen, from the ER cytosolic domain. It was also found that this translocation is negatively 
impacted by NS5A ,suggesting that NS5A influences NS4B topology (David et al., 2015).  
 
NS5A is a zinc-binding, membrane metalloprotein. This protein exhibits pleiotropic functions  
including viral replication, virion assembly, and extensive interactions with cellular processes 
such as tumorigenesis promotion and apoptosis inhibition, both of which trigger 
hepatocarcinogenic progression  (Kim and Chang, 2013; Pawlotsky, 2013). The NS5A 
phosphorylation status is considered to have a pronounced impact on its enzymatic function and 
the HCV life cycle. The phosphorylation states of the protein are thought to mediate the efficiency 
of HCV replication, seemingly through interactions with other HCV NS proteins or regulatory 
factors of the host. This protein is found in two forms: hyperphosphorylated (p58; 58 kDa) and 
basally phosphorylated (p56; 56 kDa), which are each implicated in different functions 
(Pawlotsky, 2013; Masaki et al., 2014; Masaki and Suzuki, 2015). The NS5A protein is 
subcategorised into three domains: domain I, II and III.  The NS5A protein is anchored to the 
membrane through an amphipathic helix found at the N-terminal of domain I. To date, the 
functions of domain II and III are still unknown (Scheel and Rice, 2013). 
 
The NS5B RNA-dependent RNA-polymerase (RdRp) of HCV is an essential component of the 
RNA replicase and is responsible for replication of the RNA genome (Han et al., 2014). The HCV 
RdRp protein serves as another main focus area of this work. Its structural features, expression, 
enzymatic activity, interactions with other virus-associated and host factors and the effectiveness 
of anti-viral compounds is deliberated in more detail in subsequent sections.  
 
Among all the HCV proteins, NS3 and NS5B proteins serve as the most attractive and potentially 
aspiring targets in drug design and discovery research. 
 
2.4.3 Life cycle of HCV 
The HCV is a blood-transmitted virus that reaches the liver via the circulatory system (Irshad, 
Mankotia and Irshad, 2013). The HCV virion binds to a viral receptor present at the surface of 
the host liver cell. This binding facilitates the internalisation of the viral particle through fusion 
of the viral envelop and the cellular membrane via clathrin-mediated endocytosis (Kim and 
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Chang, 2013). Once the virus gains entry to the cell, the viral particle undergoes uncoating to 
initiate the release of the HCV positive sense RNA. The RNA in question, encompasses an 
internal ribosome entry site (IRES) located in the 5'-end. This allows mimicking of the cellular 
mRNA 5'-cap, thus duping cellular ribosomes to induce translation into a polyprotein. The 
polyprotein is associated with the cellular endoplasmic reticulum (ER) and is processed by viral 
and cellular proteases into structural and non-structural HCV proteins. The HCV proteins form a 
replication machinery, which create RNA copies in a part of the ER called the membranous web. 
The newly synthesised RNA-molecules are subsequently encapsulated and gathered into new 
virion particles that mature prior to leaving the cell by means of exocytosis (Dustin et al., 2016). 
The life cycle of HCV is diagrammatically presented in Figure 4.  
 
 
Figure 4: Overview of HCV life cycle in liver cells (Adapted from Wang et al., 2017). 
 
2.5 Clinical Features 
 
2.5.1 Acute HCV Infection 
Upon infection with HCV, majority of patients will enter the acute phase. Generally, acute HCV 
infection spontaneously resolves within six months and is clinically mild or asymptomatic. Since 
this phase presents with no symptoms, its diagnosis and study with respect to the host immune 
response and viral clearance is an extremely difficult task. This is the reason as to why many 
HCV-infected patients are diagnosed only in the chronic state of infection and the time of 
exposure cannot be accurately pin-pointed (Butler et al., 2016).  Following exposure, HCV-RNA 
can be detected in the host’s serum within 1 to 3 weeks. Symptoms that may occur include: loss 
of appetite, abdominal pain, dyspepsia, jaundice and fatigue (Deutsch et al., 2013; Butler et al., 
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2016). In most cases, the symptoms are not severe and do not require medical treatment. Elevated 
alanine aminotransferase (ALT) levels are the first sign of hepatic injury and can be detected 4 to 
12 weeks after contracting the virus (Choi et al., 2016). The HCV infection is detected by the 
presence of the viral RNA in the host’s serum and through anti-HCV antibody seroconversion (Li 
and Lo, 2015). Clearance of the infection is partly influenced by host factors such as age, race, 
gender and human leukocyte antigen system; and viral factors such as genotype and co-infections 
present. The key driving force facilitating viral clearance of HCV infection is a strong cellular 
immune response of the host. It is important to note that patients who undergo spontaneous 
clearance should be monitored as relapse may occur up to 6 months after viral eradication.  
 
2.5.2 Chronic HCV Infection 
The leading cause of hepatic-related diseases is HCV. As mentioned, a rather small percentage of 
individuals have the capability to eradicate the virus following an acute infection, regrettably, the 
majority will progress to the chronic state. Chronic HCV infection may persist for several years 
without the occurrence of death.  Unfortunately, in most cases progression of the infection leads 
to hepatitis, fibrosis and cirrhosis development. Atleast 1-4% of chronically infected patients will 
develop HCC. Host-induced factors that intensify progression of hepatic damage include: 
hepatitis B virus (HBV) or human immunodeficiency virus (HIV) co-infection, race, gender, 
alcohol consumption, age and obesity (Yan and Wang, 2017). It appears that the HCV genotype 
does not influence progression of the disease, but non-alcoholic fatty liver disease can 
significantly worsen the state of the chronic viral infection (Silini et al., 1996; Patel and Harrison, 
2012).  
 
 
2.6 Pathogenesis   
In  the pathogenesis of viral hepatitis, the host immune response has a peculiar role as it modulates 
and attenuates the infection as well as contributing toward development of the chronic infection 
and hepatic cirrhosis (Park and Rehermann, 2014). Viruses are categorised as cytopathic, meaning 
cells are killed during the infection, or non-cytopathic such as HCV (Plesa et al., 2006). The HCV 
induces acute or chronic hepato-related diseases whilst intermingling with the host’s immune 
system.   
 
In the first few weeks following exposure, interactions between the host immune system and HCV 
may significantly influence the viral infection in terms of its evolution and prognosis. The 
progression of HCV infection is usually slow and may take up to twenty years before the effects 
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on the host are seen. Generally, the acute stage of the infection is asymptomatic and on rare 
occasions, may be associated with life-threatening illnesses. The acute HCV infection accounts 
for 15-45% of the infected individuals and will clear up within six months without medical 
intervention, unfortunately, an estimated 60-80% will go onto develop chronic HCV infection 
(World Health Organization, 2018).  
 
Following exposure to HCV, the innate immune response is triggered but the virus has the 
capability to comprehensibly evade the response, which leads to viral persistence (Li and Lemon, 
2013). This phenomenon takes place due to the evolution of HCV that allows the offset of retinoic 
acid-inducible gene I (RIG-1) pathway, thereby allowing the virus to elude the immune-induced 
challenge. This occurrence is the reason behind the majority of HCV-infected individuals 
progressing to the chronic state of infection. During this process, the protease domain of the NS3 
protein is activated for cleavage of interferon-beta (IFN-β) promoter stimulator (IPS-1), an 
adapter protein of RIG-1 (Park et al., 2016). Following cleavage, IPS-1 is not able to generate 
downstream signals for activation of nuclear factor kappa-light-chain-enhancer of activated B 
(NFκB) cells and interferon regulatory transcription factor 3 (IRF-3), resulting in the incapability 
of HCV-infected cells to express interferon-stimulated genes or produce IFN-β (Irshad, Mankotia 
and Irshad, 2013). 
 
Natural killer (NK) cells are key components, functional in the innate immune system. These cells 
have an important role in HCV eradication. A large population of NK cells can be found in the 
liver and are usually activated in the early phase of HCV infection. Activation of these cells leads 
to the recruitment of T lymphocytes and prompts hepatic antiviral immunity (Golden-Mason and 
Rosen, 2013; Holder, Russell and Grant, 2014). Additionally, the NK cells eliminate HCV-
infected liver cells by secreting cytokines such as tumor necrosis factor-alpha (TNF-α) and IFN-
γ or through cytolytic mechanisms. Unfortunately, HCV has adopted multiple defense strategies 
to counteract the response emanating from host NK cells. Compromised or inactive NK cells 
permit continuation of viral invasion whereas the active form of these cells contributes to hepatic 
injury (Irshad, Mankotia and Irshad, 2013). Through immunological assessments, it was 
established that onset of the adaptive cell-mediated and humoral immune response is delayed by 
1-2 months and 2-3 months, respectively. This imminent delay allows HCV to bypass the adaptive 
immune system (Cǎruntu and Benea, 2006; Dustin et al., 2016). 
Liver damage caused by HCV exist primarily in the form of inflammation. This condition is 
known as hepatitis. Chronic persistence of hepatitis leads to fibrosis (Sebastiani, Gkouvatsos and 
Pantopoulos, 2014). When hepatic inflammation occurs, stellate cells are activated. Under normal 
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physiological conditions, these cells regulate blood flow through the liver and stores vitamin A 
(vit A) and fat (Wang et al., 2013). Inflammation induced by HCV ignites reactions from all 
different types of hepatocytes, this causes stellate cells to alter their function from storing vit A 
to releasing the nutrient. During this process, cytokines are released, which in turn activates white 
blood cells (WBC) located externally to the liver. The WBCs migrate to the site of infection where 
they associate with Kupffer cells to yield chemical signals (Fujita and Narumiya, 2016). Kupffer 
cells are specialised WBCs that function to neutralise and eradicate tumorigenic cells and 
pathogens from the liver. These signals trigger collagen production by stellate cells within the 
extracellular matrix, an area suited between cells (Dixon et al., 2013). Collagen is a fibrous 
protein, the main component in scar tissue formation (Bataller and Brenner, 2005). Normally, the 
body utilises collagen at the site of infection to restrict dissemination of the infection to 
neighbouring cells. As the infection resolves, the collagen matrix encapsulating the injury is 
dissolved and activated stellate cells undergo apoptosis to allow the tissue to return to normality. 
In circumstances where chronic HCV infection is present, the collagen matrix grows at a rapid, 
uncontrollable rate and cannot be efficiently dissolved. This results in accumulation of scar tissue 
around the cells.  Eventually, hard, irregular areas of scar tissue, referred to as nodules will form 
and replace the smooth liver. The nodules disrupt blood flow to the hepatocytes causing the loss 
of valuable nutrients and oxygen that they require to survive, ultimately leading to cell death. A 
positive feedback mechanism between inflammation and fibrogenesis will cause amplification of 
fibrosis (Greener, 2013).  
 
Oxidative stress may also be a possible case of fibrosis due to the generation of free radicals 
(FRs), which are the by-product of cellular metabolic processes such as lipolysis and energy 
generation (Ivanov et al., 2013; Phaniendra, Jestadi and Periyasamy, 2015). During these cellular 
processes, oxygen is converted into FR superoxide (Phaniendra, Jestadi and Periyasamy, 2015). 
Healthy, normal cells possess protective mechanisms that act against FRs; however, increased 
production of FR will inflict damage to tissues, cellular macromolecule including proteins, 
nucleic acids and lipids (Rahal et al., 2014). In chronic HCV infection, prolonged inflammation 
may lead to FR over-production within the liver. The FRs will then attack the membranes of cells 
causing injury and cell death, thus further facilitating the progression of fibrosis (Ivanov et al., 
2013; Medvedev, Ploen and Hildt, 2016).  
 
Experimental studies have positively established a link between type 2 diabetes mellitus (T2DM) 
and HCV, patients with chronic HCV infection frequently present with this form of diabetes (Hum 
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and Jou, 2018). Insulin resistance (IR) is a condition in which cells are unable to effectively 
respond to the normal action of insulin, thus becoming resistant to the hormone (Bose and Ray, 
2014). In T2DM, IR is a common occurrence, coupled together, both significantly influence the 
state of  the chronic HCV infection by enhancing development and progression of hepatic fibrosis 
and steatosis (Kralji et al., 2016).  Many chronically infected HCV patients are noted to have 
steatosis. Hepatic steatosis is described as the excessive accumulation of lipids within the liver. 
Two forms of steatosis are present in HCV-infected individuals: (1) metabolic steatosis and (2) 
HCV-induced steatosis (Adinolfi, Restivo and Marrone, 2013). Metabolic steatosis occurs due to 
IR, hyperlipidaemia and obesity (Kralji et al., 2016). This form of steatosis is not triggered by 
HCV but its concurrence with the virus has been associated with rapid fibrosis progression. 
Metabolic steatosis can occur in all genotypes of HCV. The second form of steatosis is caused 
only by HCV genotype 3; however, the precise mechanism remains elusive, but it is understood 
that the virus directly induces steatosis through three mechanisms: impaired lipid secretion, 
elevated de novo free fatty acid synthesis and impaired degradation of fatty acids (Adinolfi, 
Restivo and Marrone, 2013; Irshad, Mankotia and Irshad, 2013). Cumulatively, this will result in 
the excess abundance of lipids that will further contribute to the steatosis endured by the patient. 
Upon treatment, HCV-induced steatosis regresses and may be entirely cleared but if relapse takes 
place, HCV-induced steatosis will reappear (Irshad, Mankotia and Irshad, 2013).  
 
The development of HCV-induced HCC can span over a 20 to 40-year period and will only 
develop in approximately 1-4% of infected individuals with chronic infection. Carcinogenesis 
inflicted by HCV is mediated by the host-induced immunological response and viral-induced 
factors (Goossens and Hoshida, 2015; Axley et al., 2018). Viral proteins of HCV are capable of 
directly interacting with cell signaling pathways to promote HCC development by upregulating 
cell division and growth or by inhibiting cell-cycle checkpoints and tumour suppressor genes 
(Hoshida et al., 2014). In addition to HCV, the host-immunological response is also modulated 
by chronic inflammation, IFNs and TNF (Yu et al., 2012). Accelerated rates of cell cycle 
repetition is often linked to the accumulation of mutations that may ultimately facilitate 
hepatocyte transformation into cancerous cells.  The most common genes that undergo mutation 
in HCC are β-catenin, tumour protein 53 (p53) and telomerase reverse transcriptase, these 
mutations compromise the efficiency of telomerase maintenance thus leading to the upregulation 
of oxidative stress leading to cell death and regeneration, which gives rise to hepatocyte mutations 
and further supports HCC development (Nault et al., 2014; Axley et al., 2018). As cells begin to 
transform into cancerous cells, they undergo increased proliferation that causes the telomeres to 
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become very short. In normal cells, if telomeres become too short, they signal arrest of 
proliferation, cells become inactive and die (Carulli and Anzivino, 2014). Contrastingly, 
malignant cells abscond apoptosis by producing more telomerase enzymes, which stops the 
telomeres from getting even shorter (Donate and Blasco, 2011). The emergence of HCV-induced 
HCC is caused by the aggregation of cirrhotic hepatocytes that harbour excessive mutations, 
which allow readmittance into the cell cycle and reactivation of telomerase, thus permitting their 
advancements through cancer checkpoints, promoting progression of HCC development. The 
development of cirrhosis and fibrosis greatly increases the risk of developing HCC (Axley et al., 
2018). The pathogenesis of chronic HCV infection is summarised in Figure 5.  
 
 
 
 
 
 
 
 
 
Figure 5: Overview 
of HCV 
pathogenesis (Prepared by Author).  
 
 
2.7 HCV NS3 
 
2.7.1 Structure, Function and Potential as a Drug Target 
The NS3 protein is a multifunctional viral enzyme, one third of the protein consists of a serine 
protease located at the N-terminal and the remaining two-thirds is an RNA helicase, positioned at 
the C-terminal of the genome. The NS3 chymotrypsin-like serine protease is accountable for 
downstream protein cleavage of junctions located between NS3/4A, 4A/4B, 4B/5A, 5A and 5B 
(Salam and Akimitsu, 2013). The protease contains the catalytic triad made up of three residues: 
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histidine 57, aspartate 81 and serine 139 that is required for efficient protease activity. The proper 
orientation the catalytic triad is dictated by the NS4A protein. This protein binds to the protease 
as a co-factor to stabilise and activate protease activity as well as to promote anchorage of NS3 
to host cell membranes (Shiffman, 2012; Rimmert et al., 2014). 
 
The RNA helicase is the larger portion of the NS3 complex and is classified into the superfamily 
2, DEXH-family of helicases. The function of the helicase is to separate the double-stranded 
RNA, using adenosine triphosphate as a molecular energy source (Byrd, 2012). Additionally, the 
helicase contains two important structural elements, the arginine clamp and the phe-loop. These 
two sequence motifs are vital for RNA or DNA binding and strand separation. Remarkably, these 
two regions are conserved across all known geno- and sub-types of HCV and they cannot be found 
in other SF2 protein families (Lam, Keeney and Frick, 2003; Frick, 2006). The NS3/4A complex 
and essential structural features are highlighted in Figure 6. 
 
Figure 6: The three-dimensional crystal structure of HCV NS3 protein complex (PDB ID: 
4B6E) highlighting important elements: the RNA helicase (green), protease (blue), NS4A 
(magenta), Arg-clamp and Phe-loop (purple), catalytic triad and the ATP-binding domain using 
UCSF Chimera software program. (Prepared by Author). 
 
The NS3 complex is essential for HCV polyprotein cleavage, in order to generate vital proteins 
required for RNA genome replication (McGivern et al., 2015).  Within infected cells, the NS3 
protein is also known to impede signaling of the innate immune recognition and response through 
cleavage of TIR-domain-containing adapter-inducing interferon-β (TRIF) and mitochondrial 
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antiviral signaling (MAVS) proteins. The TRIF and MAVS proteins act in response to 
downstream stimuli received from the toll-like-receptor 3 and retinoic acid inducible gene-I 
pathways, respectively, leading to curtailment of the host cellular interferon response (Brown et 
al., 2016; Liang et al., 2018). The NS3/4A enzyme exhibits several functions including: 
unravelling of the HCV RNA genome from the RNA binding proteins, unwinding the single-
stranded RNA with secondary structures and double-stranded (ds) RNA replication intermediates 
(Shiryaev et al., 2012; Moradpour and Penin, 2013). Therefore, the NS3/4A enzyme is recognized 
as an indispensable component of the HCV replication complex (Salam and Akimitsu, 2013). The 
NS3 protein complex modulates both the host and virus, therefore, it is considered as an attractive 
target for drug development (McGivern et al., 2015). 
 
Over the years, the scientific community has focussed mainly on the protease as a drug target. 
This strategy has been effective so far, but it has also cast a relatively large shadow over the 
potential of the HCV helicase in drug therapy. The helicase is highly essential for transcription, 
translation and RNA splicing during replication. Not only is it pivotal in replication but it also 
contains two highly conserved regions, the Arg-clamp and Phe-loop that are exclusive only to 
HCV helicase (Lam, Keeney and Frick, 2003). Thus, the RNA helicase of HCV reveals itself as 
an addition target and good candidate in antiviral drug design and development research.  
 
 
2.8 HCV NS5B 
 
2.8.1 Structure, Function and Potential as a Drug Target 
The HCV RdRp is a 66 kDa protein, which is the key enzyme responsible for RNA synthesis and 
genome replication (Han et al., 2014). The protein consists of 591 amino acids and is located at 
the C-terminal of the viral genome. Similar to other viral polymerases, the HCV RdRp adopts a 
right-handed topology and is subdivided into three domains: thumb (residues 371-561), finger 
(residues 1-187, 228-286) and palm (residues 188-227, 287-370) (Boyce et al., 2014).  
 
There are three important structural elements that are required for efficient viral replication: ˄1-
loop (residues 12-46), β-loop (residues 443-455) and C-terminal tail (residues 540-561) (Boyce 
et al., 2014). The finger domain contains an extended loop known as the ∧1-loop. The 
establishment of this interaction is imperative as it aids in communication of the two domains  
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 during translocation of the RNA. The RdRp has two enzymatic activity modes parallel to 
differing conformations. Extensive interdomain interactions between the thumb and finger 
domains prompt the enzyme to take on a closed “active” conformation. This conformational state 
provides a suitable environment for de novo RNA synthesis for viral replication initiation 
(Sesmero and Thorpe, 2015).  In 2002, Labonte et al., showed the importance of the finger loop 
by conducting experimental studies which suggested that arginine or serine substitution of leucine 
30 in the ∧1-loop disrupts interactions between the thumb and finger domains and ultimately 
prevents the closed conformation from occurring, resulting in a non-functional enzyme (Labonté 
et al., 2002).  The C-terminal is made up of hydrophobic residues and forms the RdRp linker 
region, allowing protein membrane anchorage in cells, which is responsible for ER membrane 
association during viral replication. The C-terminal residues are in close proximity to another 
regulatory motif known as the β-loop. The β-loop is designated as a non-catalytic area that 
encompasses a regulatory motif, which expedites the inhibition of RdRp activity and prevents 
RNA binding.  All three regulatory elements and domains are graphically represented in Figure 
7.   
Figure 7: The three-dimensional crystal structure of HCV NS5B polymerase (PDB ID: 3H5S) 
highlighting the three domains and important elements required for viral replication, generated 
using UCSF Chimera software program (Prepared by Author). 
 
The RdRp is viewed as an attractive target for antiviral therapeutic intervention of HCV 
associated diseases due to its distinct and exclusive ability to use the RNA template that is absent 
in host mammalian cells (Scheel and Rice, 2013; Wei et al., 2016). Currently, there are many X-
ray crystallography structures of the free enzyme as well as inhibitor-bound HCV RdRp available, 
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which provide significant support for the discovery and development of new structure-based HCV 
RdRp inhibitors (Wei et al., 2016). 
 
 
2.9 HCV therapy 
 
2.9.1 Current Therapies 
Since the discovery of HCV, numerous therapeutics have been evaluated to detect effectiveness 
in the treatment of the chronic infection. A synthetic analogue of purine, known as Acyclovir, 
was the first drug to be clinically evaluated in HCV treatment. Regrettably, the drug showed no 
significant impact in treatment of the disease. Over there years, the medicinal and pharmaceutical 
domains have been able to identify successful and potential candidates in combined or mono-
HCV therapy, these include ribavirin, interferon and direct acting antivirals that target viral 
proteins required for replication. 
 
2.9.1.1 Ribavirin and Pegylated Interferon-alpha 
Ribavirin, a nucleoside inhibitor, is a ribonucleic-guanosine analogue that is used to impede 
synthesis of viral RNA and inhibit precursor messenger RNA capping. Metabolic processing of 
ribavirin gives rise to a molecule that bares close resemblance to purine nucleotides of RNA. This 
feature allows the molecule to disrupt viral RNA metabolism, which is a process necessary for 
efficient HCV replication. Unfortunately, ribavirin is ineffective against HCV on its own (Gish, 
2006; Graci and Cameron, 2006). Interferons are naturally occurring proteins that form a vital 
part of the immune system. They function in two ways. Firstly, they hamper the process of viral 
replication and secondly, they augment immune responses. Interferons affect viral replication by 
binding to receptors presented by almost every cell type, stopping entry of the virus into the host 
cell as well as replication. These proteins are known to boost immune response by inducing 
immune cell activity, which in effect, renders the compromised cells more vulnerable to actions 
of the immune system (Hervas-Stubbs et al., 2011). Interferon produced in laboratories are 
metabolised at an exceedingly rapid rate, as a result, its effectiveness is reduced, and the virus can 
replicate during the small intervals arising between treatments. To address this challenge, IFN 
was subjected to pegylation, a process by which a large molecular chain is attached to the protein 
to slow down the rate at which it is metabolised.  Addition of the molecular chain allows consistent 
levels of the drug to be released into circulation, which projects a continual attack on the virus 
(Foster, 2010). However, many patients undergo PEGylated IFN-α therapy experienced 
debilitating adverse effects manifesting in the form of depression, headaches, shivering, fever and 
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fatigue (Nguyen and Morgan, 2012). Together, ribavirin and PEGylated IFN-α form an effective 
combined therapeutic regime against chronic HCV infection eradicating the virus in 40-50% of 
HCV-infected individuals (Palumbo, 2011). Unfortunately, the ribavirin component of combined 
therapy has prevented many HCV-infected patients from successfully completing therapy due to 
the development of gout, sinusitis, rash, itching, fatigue and haemolytic anaemia. The use of 
ribavirin has also resulted in death by myocardial infarction in those presenting with 
cardiovascular disease (Koh and Liang, 2014).  
 
2.9.1.2 Direct-Acting Antiviral Drugs 
Direct-acting antiviral drugs (DAAs) are a new class of HCV drug. These drugs function by 
directly targeting specific stages in the viral life cycle of HCV. There are four classes of DAAs: 
NS3/4A protease inhibitors (PIs), Nucleotide/nucleoside NS5B RdRp inhibitors (NIs), NS5A 
inhibitors and lastly, non-nucleoside NS5B RdRp inhibitors (NNIs) (Pockros, 2015). The current 
drugs under investigation and/or Food and Drug Administration (FDA) approved drugs are 
represented in Table 1. 
 
Table 1: Current HCV direct-acting antiviral drugs (DAAs) in Clinical Testing and/or FDA 
approved. 
 
Drug Structure Phase Class  Genotype 
 
Asunaprevir 
 
 
Phase II 
 
PI 
 
  
 
 
 
1, 4 
 
Boceprevir 
 
 
FDA approved 
 
Discontinued 
 
 
PI 
 
1 
 
Danoprevir 
 
 
Phase I 
 
PI 
 
 
 
1-6 
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Glecaprevir 
 
 
FDA approved 
 
Mavyret- 
glecaprevir, 
pibrentasvir 
 
 
PI 
 
 
 
1-6 
 
Grazoprevir 
  
FDA approved 
 
Zepatier- 
grazoprevir, 
elbasvir with or 
without ribavirin 
 
 
PI 
 
 
 
1, 3, 4 
 
GS-9256 
 
 
Phase II 
 
PI 
 
 
 
 
1 
 
Narlaprevir 
 
 
Phase II 
 
PI 
 
 
 
1 
 
Paritaprevir 
(ABT-450) 
  
FDA approved 
 
Viekira Pak- 
paritaprevir, 
ombitasvir, 
dasabuvir, and 
ritonavir 
 
Technivie- 
paritaprevir, 
ombitasvir and 
ritonavir 
 
 
PI 
 
 
 
1, 4 
 
Simeprevir 
 
 
FDA approved 
 
Olysio- 
simeprevir, 
ribavirin or 
sofosbuvir and 
PEG-IFN-α 
 
 
PI 
 
 
 
1 
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Sovaprevir 
 
 
Phase II 
 
PI 
 
 
 
1 
 
Telaprevir 
 
 
FDA approved 
 
PI 
 
 
 
1 
 
Vaniprevir 
 
 
Phase II 
 
PI 
 
 
 
1 
 
Vedroprevir 
 
 
Phase II 
 
PI 
 
 
 
 
 
1 
 
Voxilaprevir 
 
 
FDA approved 
 
Vosevi- 
Voxilaprevir, 
sofosbuvir and 
velpatasvir 
 
 
PI 
 
1-6 
 
Daclatasvir 
 
Daklinza-
declatasvir, 
sofosbuvir, 
ribavirin, and 
interferon 
 
 
NS5A 
 
1-4 
 
Elbasvir 
 
 
FDA approved 
 
Zepatier- 
Elbasvir and 
grazoprevir 
 
NS5A 
 
1, 4 
 
Ledipasvir 
 
 
FDA approved 
 
Harvoni-
ledipasvir and 
sofosbuvir 
 
NS5A 
 
1 
28 
 
 
Ombitasvir 
 
 
FDA approved 
 
Viekira Pak- 
Ombitasvir, 
paritaprevir, 
ritonavir 
 
 
NS5A 
 
1 
 
Pibrentasvir 
 
 
FDA approved 
 
Mavyret- 
glecaprevir and 
pibrentasvir  
 
NS5A 
 
1-6 
 
Velpatasvir 
 
 
FDA approved 
 
Epclusa- 
vepatasvir and 
sofosbuvir 
 
NS5A 
 
1-6 
 
ABT-072 
 
 
Phase II 
 
NNI 
 
1 
 
Deleobuvir 
 
 
Phase III 
Discontinued-
insufficient 
effectiveness 
 
 
NNI 
 
1 
 
Dasabuvir 
 
 
FDA approved 
 
Exviera- 
dasabuvir, 
ombitasvir, 
paritaprevir, 
ritonavir 
 
 
NNI 
 
  
 
1 
 
Filibuvir 
 
 
Phase II 
Discontinued-
strategic reasons 
 
 
NNI 
 
1 
29 
 
 
IDX 184 
 
 
Phase II 
 
NI 
 
1 
 
IDX-375 
 
 
Phase I 
Discontinued-
Europe 
Phase II 
Discontinued-
USA 
 
 
NNI 
 
1 
 
Mericitabine 
 
 
Phase II  
Discontinued 
 
NI 
 
1 
Setrobuvir 
 
 
Phase I 
 
NNI 
 
1 
 
Sofosbuvir 
 
 
FDA approved 
 
 
NI 
 
1-4 
 
Tegobuvir 
 
 
 
Phase II 
 
NNI 
 
1 
 
Lomibuvir 
 
 
Phase II 
 
NNI 
 
1 
 
 
Numerous HCV antiviral drugs are currently undergoing clinical trials or in some cases have been 
discontinued due to poor pharmacodynamic profiles, as stated in Table 1. Only a few HCV drugs 
have been approved by the FDA for human administration. Even though these drugs are shown 
to be successful in the treatment of HCV infection, they are only effective in a small percentage 
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of patients. Most HCV-infected individuals do not adequately respond to current market-available 
antiviral drugs due to viral genotype, onset of severe side effects and the need of frequent 
administrations (Bertino et al., 2016). The antiviral drugs are also shown to have a low barrier to 
viral resistance and lack selectivity for the virus and target mainly genotype 1 (Irwin et al., 2016). 
 
Advanced PIs, Boceprevir and Telaprevir and recently emerged, Narlaprevir, are reversible 
covalent inhibitors. Boceprevir has since been discontinued but Telaprevir in combination with 
ribavirin and INF-α are given in triple therapy to patients who were unsuccessful in previous 
therapies. There are, however, several complications with this HCV therapeutic regime. Firstly, 
Telaprevir is only effective when administered with PEGylated IFN-α and ribavirin caused by a 
low resistance barrier whereby single point mutations instigate resistance to the PI. Secondly, 
Telaprevir is only effective against specific genotypes of HCV. Thirdly, PIs are known to elicit 
side effects and lastly, triple therapy is expensive and is consequently a less attainable resource 
for patients with financial constraints. Therefore, new drugs are still required to make HCV 
treatment better tolerated and more accessible so it can tackle the global HCV burden (Hanson et 
al., 2012). 
 
2.9.2 Drug Resistance 
Viral resistance to HCV drugs has developed into an alarming problem that requires immediate 
attention. It is well known in the scientific community that viruses undergo constant modifications 
to allow cell survival and evasion of host defence mechanisms. Within humans, HCV can produce 
millions of new viruses daily. Furthermore, HCV RdRp lacks adequate proof-reading activities 
that precipitates atleast 1 error amongst every 10 000 nucleotide bases generated (Sesmero and 
Thorpe, 2015). In essence, an infected individual can potentially carry more than just one 
quasispecies of HCV (Li and Lo, 2015). This genetic variability presents a difficult task in the 
design of anti-HCV drugs as a drug may be effective against a target, diminishing its viral load, 
only for evolutionary forces to select another resistant viral quasispecies to which the drug is 
ineffective and futile (Echeverria et al., 2015). To combat this issue, a novel drug design approach 
was proposed, in this strategy, antiviral drugs were designed to specifically target a residue 
present within a biomolecular target.  This strategy attained the term, selective covalent inhibition 
and involved irreversible binding of the inhibitor to the target protein.  
 
31 
 
2.10 Covalent Inhibition 
Majority of drug discovery endeavours have culminated in the form of non-covalent reversibly-
bound drugs, although in recent years, mainstream attention has been directed toward the design 
and discovery of covalent inhibitors. Almost 30% of market-available drugs function through a 
covalent mechanism, although most of them were not deliberately produced as covalent inhibitors 
but rather discovered by chance (Singh et al., 2011; Mah, Thomas and Shafer, 2014). These 
inhibitors undergo covalent binding to a designated residue of interest located in a target protein. 
Covalent inhibitors are rapidly emerging as a valuable therapeutic approach in antiviral drug 
discovery.  Small inhibitor molecules are used as covalent inhibitors, which encompass a moiety 
that is explicitly designed to bind to an amino acid functional group of a target protein (Awoonor-
Williams, Walsh and Rowley, 2017). This manifestation occurs through conventional reversible 
or irreversible interactions while enduring the formation of a persistent non-liable bond that 
strengthens the binding affinity between the target protein and covalent inhibitor (Becker et al., 
2016; Shunmugam, Ramharack and Soliman, 2017). The diagrammatic representation of 
conventional non-covalent and covalent irreversible inhibitor binding is depicted in Figure 8.  
 
 
Figure 8: Schematic representation of conventional non-covalent (A) and covalent (B) drug 
interactions (Adapted from Bauer, 2015).  In the first step (A) The drug binds to the target protein 
through a conventional non-covalent reversible inhibitory mechanism, which results in the 
formation of a protein-drug complex. (B) A non-covalent interaction initially occurs then a 
subsequent chemical reaction takes place between the protein and drug, in doing so, a covalent 
irreversibly bound complex is generated (Bauer, 2015; Shunmugam, Ramharack and Soliman, 
2017).  
 
Inhibitors covalently bind to their target protein, consequently disassociating from it at a rate 
greater than the turnover rate of protein synthesis (Baillie, 2016).  This mechanism can be 
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observed in reactions between inhibitors and proteins carrying electrophilic “warheads” as active 
site electrophilic traps (Shunmugam, Ramharack and Soliman, 2017). These electrophilic 
warheads include aldehydes, activated ketones, alpha-ketoamides and keto-heterocycles, 
carbonitriles, and derivatives of boronic acid (Ghosh and Gemma, 2014; Baillie, 2016). 
Conversely, irreversible covalent inhibitors form adducts with their target protein which might 
not separate from the protein for the duration of its lifespan or do so with a kinetic half-life 
portentously longer than the rate of protein re-synthesis. Such compounds, frequently contain 
harder electrophilic warheads such as epoxides, α-halo ketones, acyloxymethyl ketones, 
aziridines, vinyl sulfones, and activated acetylenes, granting most irreversible covalent inhibitors 
commonly engage Michael acceptors via the Michael addition reaction (Blake and Soliman, 2014; 
Baillie, 2016). This chemical reaction is extensively used to achieve irreversible covalent binding 
and the functional groups commonly involved include propargylic acid derivatives, alkynyl 
amides, quinones, vinyl sulfonates and acrylamides (Liu et al., 2013). Currently there are 
approximately 39 covalent drugs available on the market and their associated distribution is 
graphically depicted in Figure 9 (Guterman, 2011). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: Percentage distribution of covalent drugs currently used in the pharmaceutical industry 
(Guterman, 2011). 
 
Numerous therapeutic benefits are expressed by covalent binding in comparison to conventional 
reversible binding, such as biochemical efficacy. Whereby non-equilibrium binding restricts the 
competition that may arise between elevated ligand or substrate concentrations, prolonged 
duration of drug action, requires less frequent doses, rapid target inactivation followed by prompt 
elimination, minimal drug to drug interaction, reduced occurrence of toxicities, lower drug dose 
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concentration is required, increased potency, diminished pharmacodynamic sensitivity and the 
ability to evade mechanisms of resistance (Lamarre et al., 2003; Swinney, 2004; Kumalo, Bhakat 
and Soliman, 2015; Baillie, 2016). Figure 10 displays a list of FDA approved covalent inhibitors. 
 
 
Figure 10: List of FDA approved covalent inhibitors (Kumalo, Bhakat and Soliman, 2015). 
 
Initially, the pharmaceutical industry was reluctant to pursue covalent inhibition due to major 
adjustments taking place in screening methods and concerns arising in safety. This include 
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idiosyncratic toxicity caused by target protein haptenization leading to immune system initiating 
host antibody response, reactivity will offset and prohibit any selectivity covalent modification of 
biomolecules. This will cause toxic injury leading to initiation of host cell damage response and 
immunogenicity caused by the formation of protein inhibitor adducts (Johnson, Weerapana and 
Cravatt, 2010; Johansson, 2012). Using rational drug design, scientist were able to address these 
issues which lead to the unexpected discovery of targeted viral inhibitors also referred to as 
selective covalent inhibitors (Singh, Petter and Kluge, 2010).  
 
2.10.1 Selective Covalent Inhibition 
Most selective covalent inhibition approaches have been unearthed by targeting highly reactive 
cysteine thiolate at the catalytic or non-catalytic binding site of a target protein. The purpose of 
this strategy is to appropriately and successfully address issues arising in current antiviral 
therapies. In the process of selective covalent inhibition, the thiol functional group of a cysteine 
residue is equipped with enhanced reactive properties, which makes it a perfect candidate for 
engagement of a covalent bond. The ligand is able to align an electrophilic trap with a cysteine 
residue located in the target protein (Lagoutte, Patouret and Winssinger, 2017).  The designated 
cysteine residue of the target protein must be conserved across all geno- and sub-types of the 
virus. This feature allows selective covalent inhibitors to effectively act against the virus 
regardless of geno- and sub-types as well as quasispecies that may be present within a host at a 
single given time. This feature will also be beneficial when targeting HCV on a broader, 
international scale. Thus a drug’s ability to efficiently target a specific cysteine amino acid residue 
may provide further means of attaining selectivity to  reduce the  occurrence of drug resistance to 
antiviral therapeutics (Shunmugam, Ramharack and Soliman, 2017; Shunmugam and Soliman, 
2018).
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CHAPTER 3 
 
3. Molecular Modelling and Computational Approaches to Biomolecular Structure 
and Covalent Drug Design 
 
3.1 Introduction 
Molecular modelling is one of the most rapidly growing fields in science and is considered a 
fundamental component of physio-chemical and biological research. It is comprised of numerous 
indispensable computational and theoretical tools that are combined with the principles of 
chemistry, to model and mimic biomolecular systems. By doing so, researchers are able to 
understand the atomistic and molecular behaviour of these systems, from a realistic perspective 
(Kore et al., 2012). In the last ten years, the rising expansion and subsequent popularity of 
molecular modelling is mainly owed to the substantial increase in the availability of protein 
structural data generated from nuclear magnetic resonance (NMR) spectroscopy, advanced 
electron microscopy and X-ray crystallography studies (Gorrec, 2014; Katebi et al., 2015). There 
has also been revolutionary developments in the visualisation of molecular models due to vast 
enhancements in computer hardware and software, which may allow the handling of more 
complex systems (Goldbeck, 2012; Schlick, 2013; Kozlíková et al., 2017). Although 
experimental methods can determine a biological system’s mechanism of action, the necessity of 
its application falls short due to the intensive labour, extended time periods and high-cost 
requirements. For these reasons, researchers in the scientific community have governed the use 
of computational alternatives.   
 
Drug design and discovery is a vibrant subject, cemented by its benefits of time efficient and cost-
effective means to manufacture and produce new compound molecules. Over the years, several 
computational approaches have positively impacted the field of computer-aided drug design 
(CADD) (Baldi, 2010). These approaches are divided into three categories: (1) conformational 
modelling- associated with small molecule and macromolecule complexes, (2) property 
modelling- involving physical, chemical and biological properties and lastly (3) molecular design- 
which facilitates the optimisation of these properties (Mohan et al., 2012). Thus, it can be asserted 
that computational approaches provide the pharmaceutical industry with a powerful tool, to 
accelerate drug design research for the discovery of novel drug targets  as well as  promoting the 
development of new promising drugs (Baldi, 2010; Lindahl, 2015).  
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Proceeding its conceptualisation in the 1960s, computational approaches have equipped the 
pharmaceutical industry and associated disciplines with a robust platform for drug discovery and 
in silico analysis of molecular structures (Baldi, 2010; Sliwoski et al., 2014). Rational drug design 
(RDD) adheres to a three-step process, target identification, full characterisation of target, and 
design of potential molecules that binds to the target (Todd, Anderson and Groundwater, 2009). 
The notion of RDD was founded on the basic knowledge that activities displayed by drugs are 
gained following compound binding to a protein pocket within a biological target. Thereafter, the 
conformational and chemical stability at the binding site shown by the drug directly correlates to 
its potential as a successful candidate (Stocks, 2013). The evolutionary success of RDD is 
significantly supported by the materialisation of advancements in protein crystallography, 
computational chemistry and molecular biology. The majority of the approaches employed in 
RDD were initially developed for non-covalent drugs; though, these methods can be functionally 
adapted to suit covalent drugs. However an added necessity for specialised computational 
software and tools is to establish the specialised bond between the ligand and amino acid substrate 
(Lonsdale and Ward, 2018). 
 
Structural analysis of biomolecules and RDD use numerous computational techniques including: 
molecular docking, virtual screening, multiple sequence analysis, homology modelling, covalent 
docking and molecular dynamic simulations. These techniques are widely used to understand a 
drug’s binding mechanism, from a molecular perspective. There are two major molecular 
modelling principles that are used to determine energetics and conformational modifications of 
drug-protein systems: 
 
(1) Quantum Mechanics and  
(2) Molecular Mechanics 
 
 By combining these two principles with molecular dynamic simulations, the flexibility of the 
target protein and the significance of inhibitor binding may be effectively studied.   
 
In this chapter, quantum mechanics, molecular mechanics and molecular dynamic simulations 
will be explained, thus providing comprehensive insight into the rationale underlying the chosen 
energy descriptors of this study. The principle behind the individual computational tools utilised 
in the study will also be further described. 
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3.2 The principle of Quantum Mechanics 
Quantum mechanics (QM) is one of the most successful branches of classical physics. The 
principles involved in QM were first established in the early 20th century and were categorised 
into two concepts. The first concept was conceived and developed by Planck, Born, Jordan, 
Heisenberg and Dirac, this theory was known as matrix mechanics. The second concept 
encompasses wave mechanics, which was developed by Erwin Schrodinger, to assist in the 
comprehension of quantum behaviour at a macroscopic level rather than the atomistic level 
(Tatulian, 2018).  
 
The theory underlying QM explains characteristic behaviours of subatomic constituents that make 
up all forms of matter such as photons, neutrons, protons and electrons, at a nanoscopic scale 
(Jensen, 2017). Quantum theory plays a pivotal role in biological processes within the field of 
molecular biology such as electron excitation, atomic transfer, bond formation and breakage. In 
theory, QM has the ability to predict any individual property of a system, within a 3D space. 
Mapping of electrons is carried out by the continuous electron density method and system energy 
calculations are assessed using Schrödinger’s wave function theory. When dealing with larger 
systems, electron density calculation may require the Born-Oppenheimer approximation theory.  
 
Provided below is the basic principle of Schrödinger’s wave function and Born-Oppenheimer 
approximation theory: 
 
3.2.1 The Schrödinger Wave Function  
Originally, in 1913, Niels Bohr developed an atom model, proposing that electrons are arranged 
and revolve around in fixed concentric circular orbits surrounding the nucleus, like planets around 
the sun (Figure 1 A) (Bohr, 1913). In 1926, Erwin Schrödinger, an Austrian physicist took the 
Bohr atom model one step further, by using mathematical equations for probability (Schrödinger, 
1926). This atom model was known as the quantum mechanical atom model and it suggested that 
one could only describe the probability of where an electron could be rather than define its precise 
path (Figure 1 B). Furthermore, Schrödinger also expressed that electrons were in a constant state 
of motion and didn’t have one fixed or definite position in atoms, as previously claimed by Bohr. 
(Tatulian, 2018).  
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Figure 1: Schematic representation of (A) Niels Bohr and (B) Erwin Schrödinger atom models 
(Prepared by Author).  
 
Through Schrödinger’s atom model and calculations, it was discovered that contrary to beliefs, 
electrons do not move in fixed circular orbits. Instead, electrons are in spatial regions called 
“clouds”. The first electron cloud is of the lowest energy level, denoted as 1s orbital. When an 
electron gains energy, it will jump to the next cloud, designated as the 2s orbital. From there, the 
electron will move to 2p, 3s/3p and so on. The clouds contain electrons of both low and high 
densities (Wang, 2016).  In accordance with QM, all particles are described as a wave function 
with no momentum or distinct locality, until they are observed. The probability of each potential 
observation may be discerned by the wave function (Atkins and Friedman, 2011).  
 
The fundamental basis of QM is built on the Schrödinger equation, in which the addition of atomic 
charge and mass allows prediction of nuclei and electron motions within a biomolecular system 
(Schlick, 2013; Bahrami et al., 2014).  
 
 
The Schrödinger wave equation can be represented as follows:  
 
 
 
Where: H denotes the Hamiltonian operator that encompasses derivatives with respect to the 
location of the atom, ψ is the wave function and E represents the system’s energy eigenvalues. In 
order to create a replicate of a physical model of Schrödinger’s equation, it is highly necessary 
for the wave function to be antisymmetric, normalised, mono-value and continuous. The 
Hѱ = E ѱ (Eq 3.2.1) 
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molecular Hamiltonian operator is calculated as the sum of kinetic energy (T) and the atom’s total 
potential energy (V): 
 
 
 
Where H is defined as follows:  
 
 
As observed, the Schrödinger equation is a highly complex calculation, thus its execution may be 
difficult to near impossible when dealing with molecular systems. This is due to molecular 
systems containing an excessively large number of atoms, as a consequence, the Born-
Oppenheimer Approximation is used, This QM theory compensates for the molecular structure 
rather than the atomic structure (Schlick, 2013; Bahrami et al., 2014). 
 
3.2.2 The Born-Oppenheimer Approximation Theory 
The Born-Oppenheimer approximation is one of the fundamental concepts underlying the 
description of molecular quantum mechanics.  Developed in 1927 by Max Born and Robert 
Oppenheimer, this approximation  is based on the assumption that the motion of the nuclei can 
be separated from electron motion (Born and Oppenheimer, 1927; Schlick, 2013). This theory is 
derived from the consideration of atomic particle mass and their subsequent influence they exert 
on each other. Interactions arise between the nucleus and electron, which represent the nature of 
the atom. Electrons exist at a much lighter mass in comparison to an atomic nucleus, due to their 
size, electrons have increased velocity and move almost instantaneously whereas the nuclei 
position is  assumed to be fixed due to its heavier stature (Schlick, 2013). Since the nucleus is 
heavier, it is assumed to remain at a fixed position whilst dominating and steering the electron. 
Consequently, this causes the rapid oscillation of electrons around the nucleus through nuclear 
interactive forces. Hence, the Born-Oppenheimer approximation neglects the atomic nuclei 
motion when describing atomic electrons (Scherrer et al., 2017).  This permits the resolution of 
the Schrödinger equation regarding the kinetic energy of electrons; the nuclei kinetic energy 
remains constant (Sutcliffe and Woolley, 2012).  
 
The velocity differences arising between the electrons and nuclei allow for the Born-Oppenheimer 
approximation to be applied, thus minimising the complexity of the wave function of the 
H = T + V (Eq 3.2.2) 
H =൤−
𝐡𝟐
𝟖𝛑𝟐
𝞢𝒊
𝟏
𝒎𝒋
ቀ
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Hamiltonian equation (Doltsinis, 2006; Malhado, Bearpark and Hynes, 2014). The simplified 
wave function is represented as follows:  
 
 
 
Equation 3.2.1 is converted to: 
 
 
 
Where: HEN signifies the adjustments of terms-based activity to stabilise the nuclear positions 
(VNN). Equation 3.2.5 represents EEN, deduced from the co-ordinates of the fixed nuclei and the 
unstable electrons.   
 
 
 
The electronic Schrödinger equation is used to describe molecular electronic motion. The 
accuracy of the approximation increases when applied to the electronic ground state. The fixed 
positions of interest concerning the equilibrated conformation may be evaluated once the equation 
has been solved. The potential energy surface and curve may also be established.  
 
3.2.3 Potential Energy Surface as an Application of Quantum Mechanics 
The potential energy surface (PES) is a valuable mathematical function that describes a 
molecule’s energy, nuclei probability distribution and geometry by solving the Schrödinger 
equation (Figure 2). This concept emerged from the Born-Oppenheimer approximation, in which 
electron fluctuations are dependent on the positional states of the nuclei. The PES can then be 
taken as the potential of atom motion to collide into one another, within a molecule (Atkins and 
Friedman, 2011). The graphical illustration of PES (Figure 2) exhibits regions with high potential 
energy, signifying high-energy nuclear organisation or molecular conformations and low-energy 
regions that symbolize low nuclear energy conformations. The application of PES can be put to 
practical use in computational chemistry to assess the lowest state of energy and corresponding 
positional geometry of the molecule (Jensen, 2017).  
 
 
HENѰ (relec) = EEN Ѱ (relec)   (Eq 3.2.5) 
(Hel + VNN) Ѱ (rel) = EEN Ѱ (rel)   (Eq 3.2.6) 
Ѱ (relec)  = Ѱ (relec) (Ѱ(rnucl))  (Eq 3.2.4) 
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Figure 2: Two-dimensional graphical representation of potential energy surface (Adapted from 
The California State University 2017).   
 
3.3 The Principle of Molecular Mechanics 
A major problem encountered in computational chemistry is the ability to efficiently comprehend 
the chemical characteristics of a compound, with regards to its stability, solubility and reactivity 
(Vanommeslaeghe and Guvench, 2014). To assess these features, the quantifiable dynamics must 
be observed and analysed using molecular-based models (Zimmermann et al., 2017).  
 
Molecular mechanics (MM) is simply defined as an approximation that simulates inter- and intra-
molecular interactions within a molecule by algebraic, atomistic and empirical functions. The 
concept of MM, also referred to as the forcefield method, was intentionally developed to evaluate 
the energies and geometries of large biomolecular systems using a microscopic mechanical 
model. By doing so, the simulation costs were greatly reduced when dealing with large systems 
but require multiple molecular dynamic calculations (Vanommeslaeghe and Guvench, 2014). A 
molecule is considered by MM to be a collection of balls (the atoms) being held together by 
springs (designating the bonds). Within the structure model, the molecule’s energy changes in 
response to its geometry due to the atoms repelling one another and bonds bending away from its 
natural angle or resisting the urge to be stretched.  The application of MM integrates Newton’s 
equation of motion for particles such as atoms, to describe a diverse array of molecular systems 
ranging from low molecular mass such as hydrocarbons to larger biomolecular complexes 
including nucleic acids and proteins (Vanommeslaeghe and Guvench, 2014).  
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In MM, the total energy of a compound is defined using simple algebraic terms, whilst neglecting 
the need to calculate the density of electrons and wave function, as observed in QM (Tsai, 2007). 
Various techniques are employed in RDD to determine potential drug leads prior to experimental 
testing and validation procedures. Molecular mechanic simulations also enable the development 
of atom models based on favourable energy projections (Poltev, 2017).  
 
3.3.1 Potential Energy Function 
In the force field method, atoms are designated as “building blocks” and electrons are not 
observed to be individual particles. This means that rather than resolving the Schrödinger 
equation, comprehensive information regarding the bonds should be provided instead. As 
mentioned previously, molecules are thought of as a “ball and spring” model with bonds of 
varying lengths and atoms of different sizes. It has been observed that different molecules may 
share structural similarities due the atomic make-up of the molecule.  This concept was termed 
“atom type” and it relies on the type of bonding holding the atom in place and the atom number. 
 
The force field/potential energy function of the molecular system may be distinguished by a set 
of force field equations that are based on Newton’s equation of motion. These equations can be 
used to calculate the energy of a system as well as the atomic types that create the overall 
molecule.  
 
The total potential energy encompasses all potential inter- and intra- molecular elements 
including: 
 
1. Bond stretching (occurring between atoms that directly interact with one another) 
 
 
 
2. Angle bending (relevant atoms bound to the same central atom) 
 
 
 
3. Bond torsion  
 
 
 
Er = 𝜮 Kr (r - r0)
2
 (Eq 3.3.1.1) 
Eθ = 𝜮 Kθ (θ - θ0)
2
 (Eq 3.3.1.2) 
EФ = 𝜮 K Ф [ 1+ cos (nФ – Ф0)] (Eq 3.3.1.3) 
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4. Non-bonded interaction (electrostatic and van der Waal forces) 
 
 
 
 
Where the following represents: Kr, Kθ, K Ф are force constants for bond, angle, and dihedral 
angle, respectively. The equilibrium distance, angle and phase angle are signified by r0, θ0, Ф0. 
Parameter 𝑟𝑖𝑗  is distance and  𝐴𝑖𝑗  and 𝐵𝑖𝑗 are van der Waal parameters. The molecular dielectric 
constant is represented by D and the charge points are  𝑞𝑖 and 𝑞𝑗.  
 
Typically, bonds are treated as springs and atoms as spheres in MM. The properties mentioned 
above are easier to mathematically elucidate when the atoms are treated as spheres with 
characteristics radii. The final PEF equation is therefore presented as: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Diagrammatic illustration of the total potential energy function of a molecule (Adapted 
from Saenz-Mendez et al.,2017).  
 
Currently, there are several different force fields in use; however, they vary by the type of data 
used for fitting parameters, number of cross terms and function of each energy term. The two 
most common trends that are eminent when designing force fields: 
Enb = ൤ 𝜮 𝜮൬ 𝑨𝒊𝒋𝒓𝒊𝒋𝟏𝟐  −  
𝑩𝒊𝒋
𝒓𝒊𝒋 
𝟔൰൨ + ൤ 𝜮 𝜮൬𝒒𝒊𝒒𝒋𝑫𝒓𝒊𝒋൰൨   
(Eq 3.3.1.4) 
Etotal= Er + Eθ + EФ + Enb  (Eq 3.3.2) 
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1. Force field applied to large system such as protein or DNA, possess a relatively simplified 
functional form, void of cross terms and utilises the Lennard-Jones potential as van der 
Waals energy. These are known as diagonal or harmonic force fields.  
2. Force fields applied on smaller to medium systems must uphold a high standard of 
accuracy. These types of force fields have several cross terms and an exponential-type 
potential for van der Waals energy. These are known as “Class II” force fields.  
 
The most popular and wide spread used force fields are ENCAD (Vanommeslaeghe and Guvench, 
2014), OPLS-AA (Sweere and Fraaije, 2017), CHARMM (Woodcock et al., 2007; Galindo-
Murillo, Roe and Cheatham, 2015), GROMOS (Schmid et al., 2011; Reif, Winger and 
Oostenbrink, 2013) and AMBER (Case et al., 2005, 2014). For purpose of this study, the 
harmonic AMBER force field was used for molecular system characterisation. 
 
3.4 The Hybrid Quantum Mechanics/Molecular Mechanics 
The MM approach is extremely useful when investigating non-covalent interactions of large 
biomolecular systems, this method is however not adequately equipped to handle covalent 
systems as it does not allow effective reactivity. Quantum mechanics is an essential approach that 
primarily focuses on the outcome and mechanism of chemical interactions within small model 
systems (Vanommeslaeghe and Guvench, 2014). Together, these two approaches join forces to 
create an approach that combines the speed of MM and the accuracy of QM to allow the 
understanding of chemical interactions that take place within large biomolecular systems 
(Borbulevych, Martin and Westerhoff, 2018). 
 
 The hybrid QM/MM method was first introduced in 1976 by two scientists, Warshel and Levitt 
(Warshel and Levitt, 1976; Tiziana, Russo and Prejano, 2018). In this approach, small molecules 
such as residues of interest or atoms are exposed to the QM method to allow formation of chemical 
interactions while the remaining substrate regions and solvent are coherently subjected to the MM 
method (Cao and Ryde, 2018). The advantage of employing this approach over the conventional 
QM approach is that effect of the surrounding solvent and protein is also considered, in terms of 
their influence on the geometry and local electrostatic landscape (Lonsdale and Ward, 2018).  
 
The QM/MM approach is often utilised to reveal the underlying mechanism of enzymatic 
activities, this can be beneficial in drug design, especially in relation to covalent compounds 
(Arodola and Soliman, 2017; Lonsdale and Ward, 2018). The hybrid approach is widely used and 
is very efficacious in simulation studies investigating the chemical reactivity, electronic energy 
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contributions, biochemical pathways and energy profiles of biomolecular systems (Lu et al., 
2016). Although the hybrid QM/MM approach is fast, efficient and highly cost-effective, 
advanced description by QM region has been adamantly circumvented due to the general lack of 
interpretation from reliable sources (Tuñón and Moliner, 2016).  Additionally, the free energy 
calculations involved in this approach demand vast configurational sampling. Thus, with 
biomolecular system requiring longer molecular dynamic (MD) simulations, QM/MM method is 
not a suitable option. For this study, a longer MD simulation was needed, hence the all-atom MM 
covalent approach presented as the most fitting and feasible choice. All atom covalent simulations 
has posed quite a challenge in the scientific community due to the evident lack of literature 
supporting the appropriate implementation and execution of this technique. Therefore, we present 
a cost-efficient strategy for describing covalent interactions (S Khan et al., 2018).  
   
3.5 The Principle of Molecular Dynamic Simulations 
Molecular dynamics (MD) was first introduced by Rahman, Alder and Wainwright in the 1950s 
where it was implemented for the study of liquid dynamics (Alder and Wainwright, 1957,1959). 
Since then, the field of computational chemistry has substantially advanced allowing the method 
to progress from initially only being able to simulate hundreds to thousands of atoms, to now 
being capable of simulating entire systems involving macromolecules such as proteins and DNA.  
 
There are two major types of simulation methods: classical MD and Monte Carlo (MC). A major 
advantage that reveals MD as the favoured method is the fact that it holds the ability to facilitate 
system dynamic characteristics such as time-dependent responses and rheological properties. 
Molecular dynamics is a treasured tool in molecular biology and biochemistry as it offers the 
opportunity to recognize and classify, from an atomistic perspective, the dynamic proceedings 
that may affect system properties.  
 
Classical MD integrates Newton’s equations of motion into its computational algorithm. At an 
atomistic level, MD simulations deliver high probability real-time mechanistic and 
conformational observations of chemical interactions, established through advance physical and 
mathematical algorithms. Implementation of MD simulations allows the exploration of particle 
interactions within a system, during a given time-period by generating a dynamic-based trajectory 
that is thereafter analysed. The main purpose of MD simulations is to incorporate Newton’s 
equations to solve and explain the structural dynamics and energy contributions in a molecular 
network of a system. Initial particle conditions that must be adhered to are as follows: 
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1. Boundary conditions that need to be imposed 
2. A competent force field for characterisation of interactive forces between atom, e.g. 
AMBER or CHARMM 
3. Positions and velocities of individual particles 
 
The conventional equation of motion may be solved as follows: 
 
 
 
Where: Fi represents the interactive force acting on the particle, m is particle mass, t is time-
evolution and is the position vector of the particle. 
 
The MD process is divided into four continuous technical steps, which can be repeated numerous 
times to generate a trajectory. The steps involved are as follows: 
 
1. The basic states of the biomolecular system are explained as 
- The co-ordinates of each atom 
- Bond properties between each atom 
- The accelerations of atoms 
2. The potential energy of each atom is computed. 
3. Energies obtained from step 2 are subsequently used to solve the equations of motion. 
4. The system’s new “state” needs to be retained and atom co-ordinates altered to step 
forward in the simulation. The process is then cycled back to step 1. 
 
When the trajectory is fully generated, quantitative assessment of the system’s evolution over the 
desired time-period may proceed.  
 
3.5.1 Covalent Molecular Dynamic Simulation 
Computational-based methods can describe the relationship between selective covalent inhibition 
and conformational alterations, thus offering a more reliable approach for covalent system 
exploration, opposed to standard simulation methods.  Covalent molecular dynamic (CMD) 
simulations emerged as a result of a technical modification in the conventional MD method 
allowing researchers to overcome challenges arising from covalent bond parameterisation.  
 
Fi = mi 
𝒅𝟐𝒓𝒊(𝒕)
𝒅𝒕𝟐
 (Eq 3.4) 
60 
 
The first standard, reliable protocol for covalent simulation was proposed by Khan et al., in 2018 
(S Khan et al., 2018). The protocol provided a valuable technical guideline rationalising covalent 
bond formation and corresponding system conformational changes. This strategy emphasised the 
point at which the two components, being the covalent drug and target protein, meet and interact. 
This technique has been successfully validated by several  recent publications (S Khan et al., 
2018; Shama Khan et al., 2018; Shunmugam and Soliman, 2018). The newly developed protocol 
includes suitable protein and ligand retrieval, system preparation and the final step of MD 
simulation utilising the all-atom MM approach.  
 
Not all candidates are suitable when it comes to covalent system studies, therefore it is extremely 
important to maintain a specific selection criteria when choosing a ligand and its respective target 
protein. Selection of the protein and ligand depends on the presence of reactive moieties, also 
referred to as “warheads”. These moieties are described in accordance to their action. Functional 
groups that receive electrons are deemed electrophiles and those that donate are known as 
nucleophiles. The process involved in covalent bond formation is known as Michael addition 
reaction. This chemical reaction takes place between a Michael acceptor and donor. The residues 
involved in covalent bond formation includes glutamate, aspartate, histidine, arginine, threonine, 
tyrosine, lysine and serine but the most common of all, is cysteine. The unprotonated state of 
these residues are instrumental in the process of covalent inhibition.  
 
3.5.2 Molecular Dynamics Post-Analysis 
Trajectories are created from the production run of the MD simulation. These trajectories are 
described as sequenced snapshots. They are characterised by velocity vectors and positional co-
ordinates and document the time-evolution in a multidimensional space.  
 
When selecting analytical software, there are three essential requirements: 
 
1. Qualitative visualisation software that can produce high resolution images/snapshots and 
trajectory video clips. 
2. The software should have swift processors that can handle large volumes of data. 
3. A broad variety of analysis options should be available on each program. 
 
The post-dynamic methods and calculations of interest are dependent on the nature of the MD 
study; while qualitative assessment is essential for system visualisation support.  
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For the purpose of this study, post-dynamic analysis of the trajectories are important for 
observation of: 
 
- Conformational and energetic stability of the biomolecular system. 
- Characteristics of the ligand’s binding environment and the thermodynamic energy 
fluctuations along the clustered trajectory. 
- Variability and dynamic geometric features of the biomolecular system. 
 
 
3.5.2.1 System Stability 
 
Convergence 
The term “convergence” can be used to describe protein dynamics based on bond angle vibrations 
and bond type during the unravelling of a protein. This amalgamation toward equilibrium and the 
depiction of a conformational plateau and final energetics is crucial for a MD trajectory to be 
reproducible and accurate. It is at this plateau that the ligand-protein system is shown to exhibit 
energetically stable conformations (Amadei, Ceruso and Di Nola, 1999; Sawle and Ghosh, 2016). 
 
Root Mean Square Deviation (RMSD): 
The deviation experienced by a complex may be assessed by measuring the spatial difference 
arising between two static structures within the same trajectory. The RMSD of a trajectory is 
defined as follows: 
 
 
 
 
Where: N is the total number of atoms in a complex, Ri is the vector position adopted by the Cα 
atom of particle i in the reference conformation, which is calculated following alignment of the 
structure to the original conformation (O) using the least square fitting. The average RMSD can 
be calculated by taking the average value over the number of frames in each trajectory and can be 
determined for a system’s ligand, receptor and complex (Kufareva and Abagyan, 2012; Sargsyan, 
Grauffel and Lim, 2017). 
 
 
 
𝑹𝐌𝐒𝐃 = ൭
σ ൫𝐑𝟏 − 𝐑𝟏
𝟎൯
𝟐
𝐍
𝐍
൱
𝟏
𝟐
 (Eq 3.5) 
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Radius of Gyration (RoG):  
The radius of gyration in a protein describes the root mean square distance of the atoms from their 
common centre of gravity of a given enzyme molecule. This analysis method allows the estimation of 
protein compactness along a given trajectory in a MD simulation. The equation below describes how 
RoG is assessed: 
 
 
Where: ri is the position of the ith atom and r is the centre mass of atom i. The mean value is calculated 
by taking the RoG values over the number of frames in a given trajectory (Lobanov, Bogatyreva and 
Galzitskaya, 2008) 
 
3.5.2.2 Thermodynamic Energy Calculations (Binding Free Energy) 
Binding free energy (BFE) calculations is an imperative method utilised to observe the underlying 
binding mechanism between a ligand and protein, with enthalpic and enthropic contributions 
(Schauperl et al., 2017). The estimation of BFE initiates various approaches and algorithm 
developments including molecular docking calculations, linear interaction energy, integration of 
thermodynamics and free energy perturbation.  Among the free energy calculations, the Molecular 
Mechanics/Poisson-Boltzmann Surface Area (MM/PBSA) and Molecular Mechanics/GB Surface 
Area (MM/GBSA) techniques manifest higher efficacy and accuracy abilities in estimating the 
binding free energies of biomolecular systems. The two energy terms are not reliant on a large 
training set to define different parameters. Both MM/PBSA and MM/GBSA use the combination 
of continuum solvent model and molecular model terms to estimate the absolute BFE, which is 
then averaged over the number of trajectory frames (Hayes and Archontis, 2012; Genheden and 
Ryde, 2015; Agoni, Ramharack and Soliman, 2018). The BFE (ΔG) of a biomolecular system is 
computed by the above-mentioned techniques and can be represented as: 
𝒓𝟐𝐠 =
 σ 𝒘𝒊(𝐫𝐢 − 𝐫
−)𝟐𝐧𝐢−𝟏
σ 𝒘𝒊
𝐧
𝐢−𝟏
 (Eq 3.6) 
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Where: ΔGbind is summation of the gas-phase, gas-phase energy (Egas) and the solvation energy, 
Gsol, is less the entropy (TΔS) term. The Egas is the sum of internal energy, Eint, van der Waals 
(vdW) energy, EvdW and electrostatic energy, Eele. The total solvation energy is calculated by a 
summation of the total energy contributions of polar and non-polar states (GGB and GSA, 
respectively). The GSA was determined from the solvent accessible surface area, generated by 
water probe radius of 1.4˚A. Energy determination of the polar state contributions was resolved 
by the GGB equation. The total entropy of the solute is signified as ‘S’ and temperature as ‘T’. As 
per standard protocol, the solute and solvent dielectric constants are set to 1 and 80, respectively 
(Hou et al., 2011; Zhang, Perez-Sanchez and C. Lightstone, 2017). 
 
The MM/PBSA and MM/GBSA techniques suggest quantifiable analysis of ligand binding 
affinity to the protein and is therefore able to justify molecular docked structures with logical 
reasoning (Godschalk et al., 2013; Sun et al., 2018). 
 
3.5.2.3 Conformational Features of System 
 
Root Mean Fluctuation (RMSF): 
The root mean fluctuation (RMSF) of a protein quantifies the Cα atom fluctuations of each residue with 
regard to its average position along a given trajectory (Bornot, Etchebest and De Brevern, 2011). The 
RMSF analysis provides insight into the flexibility of various protein regions upon binding of a ligand. 
The following equation is used to calculate the standardised RMSF: 
 
(1) ∆Gbind = ∆Gcomplex - ∆Greceptor - ∆Gligand (Eq 3.7.1) 
(3) Egas = Eint + Evdw + Eele (Eq 3.7.3) 
(4) Gsol + GGB + GSA (Eq 3.7.4) 
(5) GSA + γSASA 
(Eq 3.7.5) 
(Eq 3.7.2) (2) ∆Gbind = Egas + Gsol – TΔS 
𝒔𝑹𝑴𝑺𝑭𝒊 =
(𝑹𝑴𝑺𝑭𝒊 − 𝐑𝐌𝐒𝐅)
𝛔(𝐑𝐌𝐒𝐅)
 
(Eq 3.8) 
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RMSFi represents the RMSF of the ith residue, from which the average RMSF is subtracted. This is 
then divided by the RMSF’s standard deviation [σ(RMSF)] to yield the resultant standardised RMSF 
(sRMSFi). 
 
3.5.2.4 Dynamic Cross Correlation Matrix of a System (DCCM): 
Dynamic cross correlation matrix (DCCM) is a method that’s widely used to quantify fluctuations 
of residues in or out of phase during MD simulation. The co-efficient of cross correlation varies 
from anti-correlated motion (-1) to completely correlated motion (+1). The formula used to 
describe dynamic cross correlation is given below: 
 
 
 
The abbreviated terms denote the following: Cij: cross-correlation coefficient, fully correlated (-
1) to anti-correlated (+1); i: ith residue; j: jth residue; Δri: displacement vectors correspond to ith 
residue and Δrj: displacement vectors correspond to jth residue.  
 
Dynamic cross correlation plots have become a very useful method for quantification of residue 
motion that result from ligand binding or in the event of protein mutation (Kasahara, Fukuda and 
Nakamura, 2014; Tiberti, Invernizzi and Papaleo, 2015). 
 
3.6 Other Computer-Aided Drug Design Techniques Utilized in the Study 
 
3.6.1 Covalent Docking 
Covalent docking has become a valuable tool in computational chemistry especially in structure-
based drug design. The application of this docking form has garnered immense popularity due to 
the recent surge in covalent drug design and development (Shunmugam, Ramharack and Soliman, 
2017). Conventional molecular docking methods calculates the binding mode of non-covalent 
inhibitors, but this technique is rather limited because it is not capable of forming a covalent bond. 
Moreover, steric resistance arising amongst the reactive residues and covalent functional group 
may prevent the recognition of appropriate docking conformations of the ligand. At present, 
𝑪𝒊𝒋 =  
ۄ𝚫𝒓𝒊𝚫𝒓𝒋ۃ
൫ۃ𝚫𝒓𝒊
𝚫𝒓𝒋ۃۄ𝟐
൯ۄ𝟐
𝟏
𝟐
 
(Eq 3.9) 
65 
 
several covalent docking tools and platforms are available and extremely user friendly including 
DOCKTITE (Schmidt, 2014), DOCKovalent (London et al., 2014), CovDock (Zhu et al., 2014), 
Glide (Friesner et al., 2006), GOLD (Verdonk et al., 2003), AutoDock, (Cosconati et al., 2010), 
CovalentDock (Ouyang et al., 2013) and AutoDock Vina (Trott and Olson, 2010) (Shunmugam, 
Ramharack and Soliman, 2017). The covalent moiety must be loaded onto the software or online 
interface thereafter docking poses are generated in which the covalent bond is formed between 
the ligand and the target protein. Covalent docking has been successfully implemented in 
numerous studies, thus validating its important stature in CADD (S Khan et al., 2018; Lonsdale 
and Ward, 2018). 
 
3.6.2 Molecular Docking 
Molecular docking is powerful tool employed in computational chemistry especially in drug 
design research. This technique utilises multiple methods to predict binding affinity and complex 
configuration. The most common example of molecular docking application is exhibited by 
ligand-receptor complexes and can also be use regarding protein-protein complexes as well as 
drug delivery complexes in association with aptamers or nanoparticles. Molecular docking is a 
two-step process: (1) Prediction and exploration of potential ligand binding conformations in 
addition to its orientation and position at the active site of the protein. (2) The evaluation of the 
binding affinity associate with each of the predicted binding poses  (Meng et al., 2011; Ferreira 
et al., 2015).  
 
In the last ten years, there has been a drastic increase in molecular docking studies. While they 
add value to the research domain regarding structural data of new compounds or novel biological 
targets, many inconsistencies have been encountered thus questioning the reliability of its use. 
This method has faced recurrent criticism related to the inappropriate selection of small 
molecules, inapt conformational poses and unsuitable binding sites (Ferreira et al., 2015). In 
consequence to these concerns, all docked complexes in this study were further verified with MD 
simulations, followed by the demonstration of the ligand’s stability at the active site. 
 
3.6.3 Virtual Screening (VS) 
Virtual screening (VS) has a cardinal role in drug design and development research, this method 
is defined by the exploration of large-scale small molecule libraries in search of new compounds, 
based on the biological target of interest. These libraries generally contain millions of compounds 
and searching through each occupant will prove a difficult and tedious task. The VS method 
allows quick, effortless screening of these libraries, in order to filter through a smaller, more 
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feasible number of compounds that have the greatest chance as lead drugs. The objective of VS 
is achieved through recruitment of several filters, which are used to assist the identification of 
biologically active alternatives to current inhibitory compounds. This action is based largely on 
the “similar property principle”, that states that molecules with structural similarities tend to share 
similar properties.  
 
Virtual screening is divided into three approaches: (1) Ligand-based VS (LBVS), (2) Structure-
based VS (SBVS) and (3) Pharmacophore-based VS (PBVS). In the application of LBVS, 
compound libraries are generated using a well-known compound or its consequential binding 
interactions with a specific target. Contrastingly, SBVS identifies beneficial ligand binding 
affinities established at the targets active binding site. By doing so, it provides a new in-depth 
perspective into the behaviour of the active site region and ligand-protein interactions. This 
approach can positively identify selective compounds from immensely large compound libraries, 
which can then be subjected to further CADD studies. Even though both methods are innovative, 
their implementation has been associated with challenges, for instance, LBVS is known to 
generate substantially large compound libraries and identifying a possible lead drug may be a 
difficult task. Likewise, SBVS has inconsistencies such as solvation, receptor flexibility and 
entropic binding contributions, which poses a hurdle in the design of potential inhibitors against 
diseases and viruses. Recently, PBVS has gained a positive reputation accredited to its beneficial 
application in computational hit identification and lead optimisation. This form of VS is based on 
functional groups of known inhibitor compounds such as hydrophobic regions, aromatic rings, 
cations and hydrogen bond donors and acceptors. A criteria is drafted according to the 
pharmacophoric features of interest and thereafter, small molecule libraries are actively screened 
for possible hits. In this study, PBVS has been used, this approach to VS has been demonstrated 
by numerous studies, to be a much more reliable approach in comparison to LBVS and SBVS 
(Soliman, 2013; Appiah-Kubi and Soliman, 2017; Machaba et al., 2017; Ramharack and Soliman, 
2018).  
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Abstract 
Over the last two decades, covalent inhibitors have gained much popularity and is living up to its 
reputation as a powerful tool in drug discovery. Covalent inhibitors possess many significant advantages 
including increased biochemical efficiency, prolonged duration and the ability to target shallow, solvent 
exposed substrate-binding domains. However, rapidly mounting concerns over the potential toxicity, 
highly reactive nature and general lack of selectivity have negatively impacted covalent inhibitor 
development. Recently, a great deal of emphasis by the pharmaceutical industry has been placed toward 
the development of novel approaches to alleviate the major challenges experienced through covalent 
inhibition. This has unexpectedly led to the emergence of “selective” covalent inhibitors. The purpose 
of this review is not only to provide an overview from literature but to introduce a technical guidance 
as to how to initiate a systematic “road map” for the design of selective covalent inhibitors which we 
believe may assist in the design and development of optimized potential selective covalent HCV 
NS3/4A viral protease inhibitors.  
 
Keywords: Hepatitis C virus; NS3/4A viral protease; covalent inhibitors; structure-based drug design; 
selectivity
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1 Introduction 
Hepatitis C virus (HCV) has been deemed a global health concern as infection rates has escalated to 
between 170 and 185 million people worldwide 1. The progression of chronic HCV has been shown 
to facilitate the development of viral hepatitis, hepatic cirrhosis and/or hepatocellular carcinoma, 
ultimately resulting in severe liver damage 1–3. Belonging to the Hepacivirus genus and a member of 
the Flaviviridae family, HCV is a hepatotropic, positive-strand RNA virus which encodes a polyprotein 
that undergoes proteolytic cleavage to generate 4 structural proteins (C, E1, E2 and P7) and 6 non-
structural proteins (NS2, NS3, NS4A, NS4B, NS5A and NS5B) 4.   
 
Figure 1: The schematic representation of HCV genomic polyprotein organisation. The 3000 kDa 5’-
3’ untranslated region (UTR) is comprised of 4 conserved domains which translate into 4 structural 
proteins: core (C), envelope proteins 1 and 2 (E1/E2) and hydrophilic ion channel protein 7 (P7). The 
NS3/4A protease mediates the cleavage of the HCV polyprotein resulting 
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in the generation of non-structural proteins: NS2, NS4A co-factor, interferon resisting NS5A protein 
and  NS5B RNA dependent RNA polymerase 4. 
 
During the early stages of NS3/4A viral protease inhibitor research, high throughput screening/virtual 
screening technique was applied to search through vast numbers of small molecule libraries with the 
goal of generating potential lead compounds, thus speeding up the rational drug design process. In spite 
of this effort, no promising molecules were identified. The failed attempt at screening was followed by 
a strategic SBDD approach. In doing so, the approach dynamically prompted the discovery of non-
covalent inhibitors. It wasn’t until the 21st century, whereby drug discovery steered researchers on a 
path toward the discovery of covalent inhibitors. Ever since, the design and development of covalent 
inhibitors as potential drug candidates has gained great interest in the pharmaceutical industry 5,6.  
 
Covalent inhibition serves as a useful method in target identification and drug discovery 7. Small organic 
molecules are utilised as covalent inhibitors which contain a moiety that is specifically designed to bind 
to an amino acid side chain of the target protein 8. This occurs by way of conventional reversible or 
irreversible interactions whilst undergoing a bond-forming modification that intensifies the binding 
affinity between the covalent inhibitor and target protein 9. Covalent irreversible modifications of 
proteins form non-labile persistent bonds with therapeutic benefits in comparison to traditional non-
covalent reversible binding 10. Many potent inhibitors have been designed and discovered to form 
covalent adducts with target residues found in the catalytic binding site of proteases. Research into HCV 
NS3/4A viral protease inhibitors have identified three distinct examples of covalent inhibition: 
telaprevir, boceprevir and narlaprevir. However, a high level of similarity is apparent amongst HCV 
and related viral protease active sites, thus rendering covalent inhibitors less than favourable with 
respect to selectivity 11.  There is an abundance of information on covalent HCV inhibitors however 
there are limited molecular approaches that can be used to assist the design of selective covalent 
inhibitors in literature. In this review, we provide an exclusive compilation of published works over the 
last 15 years which may provide technical guidance to assist in the deliberate design of future selective 
covalent inhibitors. 
 
2 HCV protease as a critical target in drug discovery  
The catalytic protease domain of NS3/4A protease consists of residue 1-180 residue and represents the 
N-terminal of the 631 residue protein 12. The ATP-dependent RNA helicase is encoded by the larger C-
terminal of NS3 (residue 181-631) 2,4,13.  Initially, the catalytic protease domain of NS3 is inactive and 
requires co-factor NS4A, a 54 residue protein with a hydrophilic C-terminus and a hydrophobic N-
terminus 13,14 . Upon the binding of NS4A, the NS3 domain undergoes rearrangement to facilitate the 
enzymatically proficient alignment of the catalytic triad (H57, D81, and S139)13. The NS4A co-factor 
is ultimately essential for the initiation of NS3 protease activity, allowing its localisation and 
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stabilisation at the endoplasmic reticulum (ER) membrane as well as cleavage-dependent activation of 
HCV biogenesis (Figure 2) 15. 
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Figure 2: (A) The crystal structure of NS3/4A serine protease holoenzyme. (PDB ID: 4B6E).  (B) 
Representation of the protease domain of NS3 in complex with NS4A (PDB ID: 4U01). The catalytic 
triad residues of the active site are positioned in the cleft which connects the 
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helicase and protease domains. The catalytic binding site is shallow as indicated in the insert. Zinc has 
been identified as an important structural feature however its exact function is unknown.  Protease 
domain: blue; helicase domain: green; NS4A co-factor: magenta; catalytic triad: orange; active binding 
site: yellow; zinc: black 
 
In the last 2 decades, research efforts have focused on virus-encoded proteases as potential targets for 
antiviral drug therapy. The viral proteases is an absolute necessity in the life cycle of HCV either by 
effecting the cleavage of precursor viral proteins to yield functional products or by mediating the 
processing of structural proteins required for assembly and morphogenesis of viral particles. Thus the 
functional importance of NS3/4A makes it an intensively studied viral protein that represents an 
attractive antiviral drug target. Initially the preclinical efficiency of protease inhibition was 
demonstrated in HIV-infected individuals. This finding nurtured hope that other viral proteases, such 
as HCV NS3/4A, could be an ideal target for a structure-based drug design approach (SBDD).  
 
3 Non-covalent vs covalent inhibition of HCV NS3 protease 
Although immense information was available within literature on the subject of HCV proteases there 
was still a staggering lack in both development and availability of effective HCV protease inhibitors. It 
wasn’t until 1996, where a revolutionary breakthrough by Kim et al (1996) led to the publication of the 
HCV NS3/4A viral protease crystal structure 16. This ignited intense research efforts among 
pharmaceutical companies toward the identification of inhibitors for therapeutic interventions 17. 
Another massive influence that greatly impacted HCV drug discovery was the discovery of the 
protease’s vulnerability to enzyme inhibition which was identified by means of peptide product release 
from the N-terminal following substrate cleavage 18. These discoveries led to many years of exploitation 
in the direction of successful HCV protease inhibition through SBDD.  Numerous inhibitors have been 
designed to non-covalently and covalently inhibit the HCV viral protease. Most often in the case of 
non-covalent protease inhibitors, they non-selectively dock into the catalytic/substrate binding pocket. 
Contrastingly covalent protease inhibitors specifically target a certain residue at the non-catalytic or 
catalytic domain of the protein of interest.  
 
3.1 Non-covalent HCV protease inhibition 
Once the crystal structure of HCV protease became public knowledge, relentless efforts by 
pharmaceutical industries were placed toward the development of several potential antiviral candidates 
including ciluprevir (BILN 2061). Ciluprevir (Boehringer Ingelheim, Germany) was the first product-
based drug candidate to proceed to clinical drug trials in humans. The drug demonstrated a significant 
reduction of the HCV viral load thus establishing irrefutable evidence of HCV NS3/4A protease as good 
target for drug development 19. Unfortunately, ciluprevir was discontinued due to heightened occurrence 
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of cardiac toxicity exhibited at high doses within animal models. Since ciluprevir was effectuous against 
HCV, it created a fundamental understanding about the interactions occurring between protease 
inhibitors and the HCV NS3/4A viral protease. In the years to follow, ciluprevir’s chemical scaffold 
served as a template and was utilised in the development of atleast 2 non-covalent HCV protease 
inhibitors, danoprevir and simeprevir 20 (Figure 3).
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Figure 3: Examples of non-covalent and covalent inhibitors including their HCV NS3/4A protein 
target (PDB: 2OC8). All non-covalent and covalent chemical structures were obtained using 
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PubChem. Non-covalent inhibitors generally dock to the shallow binding pocket of NS3/4A 
protease and held in place by intermolecular forces. Contrastingly, covalent inhibitors specifically 
target and bind to the S139 residue located at the catalytic site of the HCV protease to initiate 
inhibition. The red arrows represent the inhibitor atom that undergoes covalent modification to 
facilitate the formation of a covalent bond between the inhibitor and S139. NS3 protease domain: 
blue; NS4A co-factor: magenta; active binding site: yellow; S139: red. 
 
Apart from conventional non-covalent inhibitors, an additional strategy was adopted and 
implemented in SBDD of HCV inhibitors. The newly found approach involved the deliberate 
integration of substrate-based inhibitors with an electrophilic war-head, for instance an alpha-
ketoamide functional group. The electrophilic war-head then acts as an active serine trap thus 
ultimately creating a “covalent” adduct or linkage between the inhibitor and target protein. This 
pioneering approach has led researchers on a promising path toward the discovery of target 
specific covalent HCV inhibitors. 
 
3.2 Covalent HCV protease inhibition 
Covalent inhibitors of HCV are characterized by the formation of an adduct, which links the 
hydroxyl group of the protease’s catalytic serine residue to the electrophilic group of the inhibitor. 
The resulting covalent complex may be categorised as either “reversible” or “irreversible” 20. 
Reversible covalent inhibitors covalently bind to their target protein, consequently disassociating 
from it at a rate greater than the turnover rate of protein synthesis 21. Conversely, irreversible 
covalent inhibitors form adducts with their target protein which may not separate from the protein 
for the duration of its lifespan or do so with a kinetic half-life portentously longer than the rate of 
protein re-synthesis 21. 
 
In the scientific community, covalent inhibitors have been subjected to wide-scale dispute due to 
the discrepancies arising from the plethora of advantages compared to expanding list of 
disadvantages. There are numerous advantage of covalent inhibitors but the following top the list: 
increased biochemical efficacy initiated by non-equilibrium binding restricts the  competition that 
may arise between elevated ligand or substrate concentrations; prolonged duration of drug action 
thereby requiring less frequent doses; increased potency; ability to bind to shallow substrate 
binding sites and to avoid mechanisms of 6,19,21,22. The cons of covalent inhibitors range from 
idiosyncratic toxicity caused by target protein haptenisation leading to immune system initiating 
host antibody response, reactivity that offsets and prohibits any selectivity that causes toxic injury 
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ultimately resulting in the initiation of host cell damage responses and lastly immunogenicity 
caused by the formation of protein inhibitor adducts  23,24.  
 
In HCV drug development, the most detrimental adverse effects of covalent inhibitors are 
increased toxicity levels and off-target reactivity. However, recent studies have identified 3 
distinct novel HCV protease inhibitors: telaprevir, boceprevir and narlaprevir that have re-centred 
the focus on covalent inhibitors 6. All 3 covalent HCV protease inhibitors target the catalytic 
binding site, more specifically serine at position 139 (S139) (Figure 3). Following the binding of 
the covalent inhibitors to the HCV viral protease, the alpha-ketoamide forms a reversible covalent 
linkage with S139. Unfortunately, this particular serine residue is conserved across all proteases 
and is therefore susceptible to complications emanating from the lack of selectivity (Figure 4)  11.   
 
 
Figure 4: Alignment of NS3 viral protease sequence from 4 members of the Flavivirus family. 
S139 is conserved within most proteases however C159 is only present in the HCV NS3 protease 
sequence. DV: Dengue virus; WNV: West Nile virus; S: serine 139 (red); C: cysteine 159 (blue); 
* indicates identical residues.  
 
4 Exploring the concept of “selective” covalent inhibition 
The design of selective covalent inhibitors is appealing concept but in practice, it is considerably 
harder to achieve. This may primarily be caused by the difficulty arising in maintaining the correct 
balance between selectivity and reactivity 23.   
Hagel and co-investigators (2011) were the first to report on a protease inhibitor forming a 
covalent linkage with a targeted cysteine residue located at the non-catalytic site, outside the 
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designated active site 11,25. The targeted cysteine residue was identified as nucleophilic C159 and 
it is conserved across all 919 HCV NS3 sequences to date. Even though structural similarities are 
observed between HCV NS3/4A and the host proteases, C159 is structurally unique to only the 
HCV NS3/4A viral protease (Figure 4 and 5). Thus it was determined that C159 was an ideal 
target for obtaining selectivity between HCV and host proteases 11.  
 
The researchers in this study were able to experimentally design and identify compound 3 (IC50 
= 2nM) as a potent selective covalent HCV viral protease inhibitor. Compound 3 contains an 
electrophilic acrylamide via a D-alanine linker which aids in increased conformational restraint 
of the molecule. To validate the findings of the selective covalency of compound 3, Hagel et al 
(2011) tested the compound against a NS3 viral protease harbouring a serine substitution at 
position 159 (C159S) 11. The results revealed compound 3 was unable to bind covalently to C159S 
thereby confirming its unequivocal selectivity for C159 of the HCV viral protease 11. 
 
 
 
Figure 5: Sequence alignment comparing HCV viral protease with Homo sapien derived 
cathepsin K protease. Cathepsin K is 1 of 500 proteases found in Homo sapiens and is functional 
in bone resorption. As depicted, there are some structural similarities (green) however cathepsin 
K lacks S139 (red) and C159 (blue). * indicates identical residues. 
 
5 In silico approach for the design of selective covalent HCV inhibitors 
In this section, we provide technical guidance as to how to initiate a systematic road map for the 
design of selective covalent inhibitors. These are typical procedures however some of the steps 
require further modification in accordance to the protein of interest, inhibitor under investigation 
and the resources available. 
 
5.1 Target Identification 
The first step is target identification. There are many bioinformatic resources available that can 
be utilised for this step.  Characteristically, the acquisition of the target protein’s crystal structure, 
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in this case, HCV NS3/4A viral protease complex can be obtained from RCSB protein data bank 
26. If the crystal structure of the target protein is not available, a proposed structure can be 
modelled through bioinformatic and homology modeling software (Table 1).  Secondly, it is 
imperative to identify the substrate-binding domain including active site residues of the target 
protein. This can be extrapolated from literature or identified using programs specialised in 
substrate-binding domain identification (Table 1).  
 
5.2 Ligand recognition 
The second step of designing a selective covalent inhibitor is to identify the ligand or inhibitor of 
interest. There are several identification approaches available however in our research laboratory, 
we rely on 2 main ligand identification approaches. The first approach encompasses the direct 
modification of published HCV protease inhibitors, through the addition of a covalent war-head 
by means of molecular modeling. The apposite position of the covalent war-head on the inhibitor 
molecule is dictated by prior literature pertaining to the binding mode with the target protein’s 
non-catalytic C159 residue. Alternatively, the second approach involves the use of high 
throughput screening (HTS) also known as virtual screening, to identify a set of non-covalent 
HCV viral protease inhibitor templates. The templates will subsequently be converted to potential 
covalent inhibitors through molecular modeling, followed by the structural addition of a covalent 
war-head 26,27.  
 
5.3 Covalent Docking 
Covalent docking is considered a critical topic in literature and forms a challenging task. In our 
previous reports we have highlighted the merits and pitfalls associated with covalent docking 6. 
To date, multiple different computational tools can be implemented in covalent docking for the 
sole purpose of potential drug discovery. The most common approach is the “link atom” tactic. 
In this approach, a “link atom” is designated in both the inhibitor and target protein. This compels 
the link atom of the inhibitor to occupy the same spatial arrangement as the target protein’s link 
atom in order to simulate covalent binding. Molecular docking software program such as GOLD 
implements this in silico approach 28.  Another widely utilised molecular docking program is 
AutoDock Tools. This program applies two methods during covalent docking: (1) a “grid-based” 
method and (2) flexible side chain modification. In the grid-based method, an attachment atom of 
the target protein and grid-based energy are the focal aims of a Gaussian based function for 
proclivity of the inhibitor’s covalently bound pose. With regard to the flexible side chain method, 
the covalently bound inhibitor and protein attachment are both perceived as one flexible side chain 
and experimented as part of the receptor 29. The shortcomings of these covalent docking 
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applications are the need for manual preparation of the inhibitor/ligand and target protein as well 
as the designation of the reactive atoms and type of reaction 30. The 2 mentioned programs, 
Autodock Tools and GOLD may adequately function in covalent docking but have major 
constraints in their accuracy, functionality and overall usefulness. Additionally, since manual 
preparation is a prerequisite, the lack of automation in the experimental system can hinder the use 
of covalent docking progression. A molecular docking software program, CovalentDock, has 
addressed these issues by automating the  preparation of ligand files 6,30.  
 
The basic mechanism involved in covalent interactions is the initial non-covalent binding of the 
inhibitor to the target protein.  Non-covalent docking of the inhibitor can be achieved through 
virtual screening software, AutoDock Vina, whereby the inhibitor is docked into the target 
protein’s specified non-catalytic binding  site 31. UCSF Chimera can then be utilised to acquire 
the values of the grid box parameters 32. The resultant compound assumes a pose that provides 
beneficial optimum reaction for selective docking. The second step of the process is covalent 
docking by way of CovalentDock 30. Once the binding affinities are established for the covalently 
docked ligand, the conformation with the highest binding affinity (lowest binding energy) should 
be selected for molecular dynamic (MD) simulations 33. Other than CovalentDock, there are 
several additional molecular docking software programs available to assist with covalent docking 
(Table 1).  
 
5.4 MD: Quantum Mechanic/Molecular Mechanics Simulation 
In silico MD simulations are carried out to further the understanding of protein-ligand complex 
properties in terms of its molecular structure, intermolecular interactions and electronic 
rearrangement 34,35. Quantum Mechanic/Molecular Mechanic (QM/MM) implementation is a 
newly emerging topic in drug discovery. Recently, in 2017, we have produced a report which has 
focused on and highlighted advantages associated with the application of QM/MM in drug design 
36. The QM/MM simulation is a hybrid technique that is widely held for the study of biomolecular 
system modeling and chemical interactions in proteins and within solutions. This approach 
combines the accuracy of quantum mechanics and the speed of molecular mechanics 35,37. In 
QM/MM, the system’s region in which harbours the chemical process is treated at an appropriate 
level of theoretical quantum chemistry whilst the  remaining system is described by a molecular 
mechanical force field such as Amber 35. Several other force fields may be applied, depending on 
the investigator’s preference (Table 1).  
 
5.5 Post Dynamics Analysis  
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Post-dynamic analysis of the trajectories obtained from MD simulation is vital in defining the 
relative binding free energies, dynamic conformational attributes and configurations, and to 
determine the state of thermodynamic equilibrium of biomolecular systems 38. 
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Figure 6: Summarised workflow adopted in silico by selective covalent inhibitor drug design.
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Table 1: In silico software available for SBDD of selective covalent HCV viral protease inhibitors. 
 
In silico method Software available 
Target identification RCSB Protein DataBank39 
Bioinformatics and Homology modelling Sequence alignment- Clustal Omega40, MUSCLE 41, 
MAFFT 42, COBALT 43, T-COFFEE 44; Model 
construction- RaptorX 45 , MODELLER46, SWISS-
MODEL 47 
Substrate binding domain identification MetaPocket 48,  Site-hound 49,  3DLigandSite 50, CASTp 51, 
PocketPicker 52, LigAsite 53, FINDSITE 54 
Molecular graphic systems UCSF chimera32, Avogadro 55, VMD 56, PyMOL 57 
High throughput/Virtual screening ZINC 58, PubChem 59, ZincPharmer 60, ChemSpider 61, 
DrugBank 62, ChEMBL 63 
Covalent Docking software AutoDock29, AutoDock Vina31, CovalentDock30, 
GOLD28,64, Glide65, CovDock10, DOCKTITE 66 
QM/MM simulation software Amber 67,68, Gromacs 69, ADF 70, NWChem 71,  
CHARMM/Q-Chem 72, ChemShell 73 
 
 
6 Conclusion 
An overabundance of information is available on covalent HCV viral protease inhibitors however it is 
not able to conceal difficulties arising from the evident lack of selectivity. Covalent targeting of non-
catalytic cysteine residues has transpired as an effective strategy for obtaining selectivity in HCV viral 
protease inhibitors. This strategy is the first of its kind to describe multiple in silico molecular 
approaches and applications that may cumulatively assist in the deliberate design of selective covalent 
HCV viral protease inhibitors.  In the future, it is with great hope that this approach may give insights 
on how to design a new generation of highly selective covalent inhibitors for other protease family 
members and a diverse range of protein families.  
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Abstract 
 
Background: Hepatitis C Virus (HCV) has raised alerting concerns over its emerging pandemic status. 
Current market-available drugs lack specificity, stability and potency. The HCV NS5B RNA-dependent 
RNA polymerase (RdRp) is a vital component in viral replication and is often targeted in antiviral 
therapies. Recent experimental procedures have led to the discovery of a novel covalent RdRp inhibitor, 
compound 47, which selectively targets cysteine 366 of HCV RdRp and exhibits promising 
pharmacokinetic outcomes. Selective covalent inhibition of HCV is, however, a highly neglected 
domain in literature that is intensified by the evident lack of efficient structure-based drug design 
protocols. Herein, we provide an atomistic insight into a novel selective approach to inhibit HCV RdRp. 
Methodology/Results: Covalent molecular dynamic analyses revealed the inhibitory mechanism of 
compound 47 on the RdRp. Inhibitor binding induced distinctive internal movements resulting in the 
disruption of normal physiological interdomain interactions. Conclusion: Compound 47 stimulates 
reorganization of key protein elements required for RNA transcription, thus hampering viral replication 
as well disrupting the overall conformation of HCV. This study will open a new avenue for the design 
of novel selective inhibitors against HCV as well as other viral families. 
 
Keywords: Hepatitis C virus, polymerase, selective covalent inhibition, antiviral research
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1 Introduction 
 
Hepatitis C virus (HCV) is a membrane-bound, hepatotropic RNA disease 1. Over the years, proceeding 
its initial discovery in 1989 2, HCV has garnered global concern over its pandemic ascent. It has been 
approximated that at least 3% of the world’s population have been infected with HCV, of which a 
further 30% will go on to develop severe hepatic-related diseases including cirrhosis and hepatocellular 
cancers 3.  
 
The HCV genome is translated into a polymer entailing 3010 amino-acid residues, which are cleaved 
by both viral and cellular proteases to generate proteins necessary for replication and viral assembly 4,5. 
Amid these proteins, is the non-structural 5B RNA-dependent RNA polymerase (NS5B RdRp). The 
RdRp of HCV is a 66kDa protein comprised of approximately 591 amino acids and is located at the C-
terminal of the viral genome. The RdRp occupies a distinguishable three-dimensional structure that 
embraces a right-handed topology with distinctive domains recognized universally as the finger, palm, 
and thumb regions 6 (Figure 1). 
 
 
Figure 1: Graphical representation of right-hand x-ray crystallography structure of NS5B RNA 
dependent RNA polymerase (PDB ID: 3H5S). The active site is denoted by *. 
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Identified as an essential component of the HCV viral life cycle, RdRp adopts a vital role in facilitation 
of RNA genome replication and transcription. The RdRp has two modes of enzyme activity that 
corresponds to the different conformations. Extensive interdomain contact between the finger and 
thumb domains facilitate the enzyme’s closed “active” conformation, which permits the de novo 
synthesis of RNA for initiation of viral replication.  On the other hand, the enzyme adopts a more open 
conformation by displacement of the C-terminal tail that also serves as the linker region and the β-loop. 
In literature, the open conformation of RdRp is still an ongoing investigation and very little is 
understood at this moment however evidence seems to suggest that this state is an indication of enzyme 
inactivity as intramolecular domain interactions vital for the initiation of replication is disturbed 7. Thus, 
RdRp and its conformation serves immense importance in viral replication, for this reason, it is  
frequently targeted by the medicinal chemistry and pharmaceutical industry for the design and 
development of potent antiviral therapies 8.   
 
Over the last twenty years, several drug candidates have been discovered and implemented in HCV 
therapeutics. The drugs are classified into two distinct classes: nucleoside/nucleotide inhibitors (NIs) 
and non-nucleoside inhibitors (NNIs), categorization is dependent on the mechanism of action 9. The 
NIs serves as imitator substrates for the RdRp to avert RNA chain elongation through nucleoside 
triphosphate displacement 10. Notable NIs include valopicitabine (Indenix), Balapiravir (Roche), 
Mericitabine (Pharmasset/ Roche) 11,12 and Uprifosbuvir (Merck & Co) 13,14. Contrastingly, NNIs 
preferably bind to allosteric sites in the RdRp palm or thumb domains, initiating conformational 
modifications of the enzyme, which hinders its function in the initiation of RNA synthesis 10. Examples 
of NNIs include ABT-072, setrobuvir and dasabuvir 15,16.  
 
Although the current market available HCV RdRp inhibitors exhibit potent activity against the viral 
enzyme, their poor chemical stability and relatively high molecular weights have led to challenges 
arising in pharmokinetics especially concerning drug absorption, distribution, biotransformation and 
elimination 17,18. Furthermore, the evolution and adaption of HCV in favour of survival has primed the 
onset of mutations at numerous sites leading to genetic variability amongst genotypes. A process that’s 
further escalated by RdRp’s lack of adequate proofreading capabilities hence the enzyme is unable to 
correct mechanistic errors, this may potentially lead to multiple genetic variations of the virus within a 
single infected individual 19. The generation of HCV mutant forms have actively endorsed the resistance 
of the virus to non-selective enzyme inhibitors 20,21. In due course, researchers developed a new 
therapeutic approach that specifically targeted RdRp of multiple if not all HCV geno- and sub-type, 
later signified as selective covalent inhibition. In theory, the approach appeared to fulfill all aspects 
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lacking in current therapies however its practicality was certainly questioned due to difficulties 
encountered during its implementation in drug discovery as a result of scarce availability of competent 
protocols 22. 
 
Selective covalent inhibition involves the binding of an inhibitor possessing a highly selective nature, 
to a residue belonging to a serine or cysteine amino acid in the protein of interest. The designated amino 
acid can be extrapolated from literature whereby experimental investigations reveal its conservative 
nature across multiple genotypes of a virus. The resultant bond formed between the two components 
are well-thought-out as an irreversible drug-protein interaction 23.  In 2006, Lee and co-investigators 
were the first to identify the importance of cysteine 366 (Cys366) in specific targeting of HCV RdRp 
24. The study discovered that mutation of cysteine to glycine (C366G) results in drastic loss of wild-
type RdRp enzyme activity. These findings profoundly disclosed the importance of Cys366 in selective 
inhibitor binding and full enzymatic functioning of HCV RdRp. The Cys366 amino acid residue is 
conserved across all HCV RdRp sequences known to date (Figure 2).  Thus rendering Cys366 as an 
ideal target for obtaining selectivity in covalent HCV inhibition 24. However selective covalent 
inhibition in association with HCV RdRp has not yet been adequately investigated, which is evident by 
the cavernous lack of subsistence within literature. This breach in science has negatively impacted the 
design and discovery of potentially effective HCV antiviral therapies 25,26.
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Figure 2: Sequence alignment of NS5B polymerase. Cysteine 366 is conserved within all genotypes of 
HCV. C: cysteine (red); Yellow star indicates identical residues. The genome sequences for each of the 
HCV genotypes were obtained from UniProt and subsequently aligned using ClustalW2 27,28. 
 
Soon after its discovery, Chen et al (2012), issued substantial findings supporting the concept of 
selective covalent inhibition and specific targeting of RdRp Cys366 6. The study involved synthesis of 
inhibitors as part of structure-activity relationship optimization (SAR) program, this sequentially led to 
the discovery of 3-(1,2-Dihydro-2-oxo-3-pyridinyl)-5-ethyl-1-[(2-fluoro-5-nitrophenyl)methyl]-1H-
indole-2-carboxylic acid,  better referred to as compound 47 (Figure 3). The covalent inhibitor’s global 
experimental profile revealed propitious in vitro safety, PK and potency. To date, there is no 
experimental data investigating the structural dynamic entities regarding compound 47 and RdRp 
interactions.
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Figure 3: Two-dimensional structural representation of HCV RdRp covalent inhibitor, compound 47. 
Red: C-3 pyridone ring; Blue: indole core and Yellow: benzene ring. The compound exhibited covalent 
binding to RdRp whereby the thiol group of Cys366 attacked the benzene ring at the position para to 
the nitro group and the fluoro group is released presumably through an aromatic nucleophilic 
substitution reaction 6. 
 
In this study, we investigate for the first time, selective covalent inhibition of HCV RdRp. Through 
extensive application of various molecular and bioinformatics tools, we expressed and compared RdRp 
dynamic and structural characteristics of the free enzyme as well as a covalently-bound complex. This 
study will emphasize the importance and necessity of selective covalent inhibition in antiviral therapy. 
It is with great hope that this study will aid in the design and development of potent, target-specific 
covalent inhibitors against HCV as well as a wide variety of other viruses. 
 
2 Computational Methodology 
2.1 System preparation  
The HCV RdRp and the three-dimensional structure of the experimental HCV inhibitor, compound 47, 
were obtained from RSCB Protein Data Bank (PDB code: 3H5S and 3TYQ, respectively) 6,29. The apo 
system contains only the free enzyme. The bound system’s protonation states was optimized, directly 
followed by the addition of hydrogen atoms  through Protein Preparation Wizard in Maestro 30,31. 
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Molecular docking was utilized to envisage binding affinities and optimized conformations of 
compound 47 within the RdRp active site 32 (grid  box  spacing  of  0.375  Å  and  x,  y,  z  dimensions  
of  9  x  9  x  7.72).  Docking software utilized in this study included AutoDock Vina 33 and UCSF 
Chimera 34. Compound 47 was subsequently docked in the active binding site of RdRp and the resultant 
complex accompanied by the most negative binding energy (kcal.mol-1) was selected and subjected to 
molecular dynamic simulations.  
 
2.2 Molecular Dynamics Simulation 
Molecular dynamic (MD) simulations provide a powerful tool aimed at the exploration of the physical 
activity perpetrated by molecules and atoms. Thus providing a focused perspective into the 
biomolecular processes of biological systems 35. The Amber14 package 36,37 was used to perform a 200 
nanoseconds (ns) MD simulation for the apo and bound system. The MD simulation was performed 
using the GPU version of the PMEMD engine provided through Amber and the FF14SB Amber force 
field. The antechamber module was utilised to generate partial atomic charges for the compound 47 by 
applying General Amber Force Field (GAFF) and restrained electrostatic potential (RESP) procedures 
38. The LEaP module was utilised to neutralise and solvate the both the apo and bound system systems 
through the addition of hydrogen atoms, sodium and chloride ions. Owing to the blatant lack of effective 
protocols within literature, for efficient selective covalent inhibition, we devised an in-house protocol 
to enhance in silico outcomes of selective covalent inhibitors. A greater expansion of the mentioned 
protocol can be found in the referenced articles 39,40.  The covalent system topology and input co-
ordinate files were created using Dabble 41. To begin with, the covalently bound system was minimized 
in two steps with the restraint potential of 10 Å for consideration of solute molecule using 500 steepest 
descent steps, followed by 1000 steps of conjugate gradient minimization. The system was then 
gradually heated from 0 to 300 Kelvin (K) and 2.5ns of equilibration was executed for apo and bound 
system stabilisation. Potential harmonic restraint of 10 kcal.mol-1 Å2 for solute atoms and Langevin 
thermostat with collision frequency of 1 ps was applied to the system.  The pressure and the number of 
atoms were kept constant to bear resemblance to an isobaric–isothermal ensemble (NPT). The pressure 
of both the systems were maintained at 1 bar using the Berendsen barostat 42 and the SHAKE algorithm 
was utilised for hydrogen bond constraint 43.  
 
2.3 Post analysis 
The coordinates of the apo and bound systems were each saved every 1 ps for which the trajectories 
were analysed using CPPTRAJ and PTRAJ modules in the Amber14 package. Analysis was conduction 
for the following: root mean square deviation (RMSD), root mean square fluctuations, radius of 
gyration, dynamics cross correlation matrix, template channel width, interdomain angle and solvent 
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accessible surface analysis (SASA). Visualisation and graphical software programs were utilised 
throughout this study including visual molecular dynamics (VMD)44 to visualize projected trajectories; 
Maestro31 software for preparation of the systems and lastly Origin software (OriginLab, Northampton, 
MA) for the plotting and generation of graphs.  
 
2.3.1 Root mean square fluctuation (RMSF) 
The fluctuation of individual enzyme residues regarding its average position within a given MD simulation is 
referred to the root mean square fluctuation (RMSF) 45. The RMSF analysis provides insights into the 
flexibility of various regions of the HCV RdRp upon binding of the ligand and is mathematically calculated 
as follows: 
𝑠𝑅𝑀𝑆𝐹𝑖 =
(𝑅𝑀𝑆𝐹𝑖 − RMSF)
σ(RMSF)
 
RMSFi represents the RMSF of the ith residue, from which the average RMSF is subtracted. This is then 
divided by the RMSF’s standard deviation [σ(RMSF)] to yield the resultant standardised RMSF (sRMSFi). 
 
2.3.2 Radius of Gyration (RoG) 
The RoG describes the root mean square distance of the atoms from their common center of gravity of a given 
enzyme molecule. This method of analysis allows the assessment of protein compactness along a given 
trajectory in a MD simulation. The equation below describes how RoG is estimated: 
r2g =
 σ 𝑤𝑖(ri − r
−)2ni−1
σ 𝑤𝑖
n
i−1
 
Where: ri is the position of the ith atom and r is the center mass of atom i. The mean value is calculated by 
taking the RoG values over the number of frames in a given trajectory 46.  
 
2.3.3 Dynamic cross-correlation matrix (DCCM) analysis  
Dynamic cross correlation is a method that’s widely employed in MD simulations to effectively 
quantify the correlation co-efficient of motion between the atoms of a protein.  The dynamic cross 
correlation between the residue-based fluctuations during simulation was calculated using the 
CPPTRAJ module incorporated in AMBER 14. The formula used to describe dynamic cross correlation 
is given below: 
𝐶𝑖𝑗 =  
ۄΔ𝑟𝑖Δ𝑟𝑗ۃ
൫ۃΔ𝑟𝑖
Δ𝑟𝑗ۃۄ2
൯ۄ2
1
2
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The abbreviated terms denote the following: Cij: cross-correlation coefficient, fully correlated (-1) to 
anti-correlated (+1); i: ith residue; j: jth residue; Δri: displacement vectors correspond to ith residue and 
Δrj: displacement vectors correspond to jth residue. The resultant DCCM of each system was constructed 
using Origin software. 
 
2.3.4 Thermodynamic Binding free energy calculations 
Molecular dynamic simulations allow admittance to free energy differences which controls the 
underlying mechanism of all biological processes 47. Calculations for binding free energy (BFE) is an 
imperative method utilised to observe the in-depth binding mechanism between a protein and ligand, 
all-encompassing both enthropic and enthalpic contributions 48. Estimation of the binding affinity within 
a docked system is calculated through BFE using the Molecular Mechanics/GB Surface Area 
(MM/GBSA) technique. This method can be utilized to provide reproducible relative binding affinities 
of compounds with respectable accuracy and requires substantially less computational resources in 
comparison to a full-scale MD free energy perturbation/thermodynamic simulation 49.  In this study, 
BFE was averaged over 20 000 snapshots, which were generated from the 200ns trajectory. The explicit 
solvent employed in the MD simulation was discarded and substituted with a dielectric continuum as 
per MMGBSA protocol 50. Changes in each term between the apo and bound states were calculated and 
contributed to the total relative BFE 49,50. Molecular mechanics force fields were then employed to 
calculate energy contributions from the atomic coordinates of the ligand, receptor and complex in a 
gaseous phase. The equations below elaborate the process in which the binding free energies (ΔG) were 
assessed:  
(1) ∆Gbind = ∆Gcomplex - ∆Greceptor - ∆Gligand 
(2) ∆Gbind = Egas + Gsol – TΔS 
(3) Egas = Eint + Evdw + Eele 
(4) Gsol + GGB + GSA 
(5) GSA + γSASA 
 
Where the following terms are referred to: ΔGbind is gas-phase summation, gas-phase energy (Egas) and 
the solvation energy, Gsol, is less the entropy (TΔS) term. The Egas is the sum of internal energy, Eint, 
van der Waals (vdW) energy, EvdW and electrostatic energy, Eele. The total solvation energy is calculated 
by a summation of the total energy contributions of polar and non-polar states (GGB and GSA, 
respectively). The GSA is calculated by means of the solvent accessible surface area, generated by water 
probe radius of 1.4˚A. Resolution of GGB equation allows the determination for the energy contributions 
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of polar states. The total entropy of the solute is denoted as ‘S’ and temperature as ‘T’. The solute and 
solvent dielectric constants are set to 1 and 80, respectively 51,52. 
 
The MM/GBSA method was also used to calculate final energy per-residue decomposition 53. 
Regarding the estimated relative binding free energies, the degree of accuracy may be enhanced if the 
terms in the equation, particularly those in Equation 2, are averaged over several MD snapshots but 
typically depends on the research of interest 50.  Conduction of separate MD simulations for the receptor, 
ligand and complex will produce more accurate BFE results, however it requires greater computational 
resources which were not readily available for this study 49,50. Though the MM/GBSA technique lacks 
the required accuracy for absolute BFE estimates 51,54, several of our previous reports including studies 
from our research group have successfully employed the MM/GBSA approach in obtaining relative 
BFE for MD simulated systems which have been validated with experimental findings 38,49,55–59. To 
obtain individual residue contribution to the total BFE profile of compound 47 with the HCV RdRp, 
per-residue free energy decomposition was performed at an atomic level for all-important residues using 
the MM/GBSA method using Amber14. 
 
3 Results and Discussion 
3.1 Stability of NS5B RdRp apo and bound system. 
Molecular dynamic (MD) simulations yield comprehensive insights into the structure and dynamics of 
a biological system. The convergence of a system may be reached as the system gains stability, often 
occurring in an increasingly longer MD simulation. Therefore, the structural dynamic examination of a 
system is highly dependent on the timescale of the MD simulation 60. Throughout the 200ns simulation, 
the root mean square deviation (RMSD) of the C-α (alpha carbon) backbone were observed for both the 
apo and bound systems. The RMSD analysis was used to graphically monitor system convergence 61. 
Both the apo and bound systems converged at approximately 30 and 35ns, respectively (Figure 4).    
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Figure 4: RMSD plot of C-α atoms of the apo and bound systems. 
 
3.2 Conformational fluctuations of NS5B RdRp  
To determine whether binding of compound 47 affects residue dynamic behavior, the root mean square 
fluctuation (RMSF) values of the apo and bound systems were analysed. The RMSF with respect to the 
averaged MD simulation conformation is utilized as a mean to demonstrate the differences arising in 
the flexibility of the residues. The RMSF of all residues were calculated for structure backbone 
flexibility and was represented as Figure 5.
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Figure 5: Residue-based average C-α fluctuations of the apo and bound conformation of HCV RdRp 
throughout 200ns MD simulation.  
 
Higher C-α fluctuation values signify more flexible movements in relation to the average position of 
the residues, contrastingly, reduced values express restricted fluctuations during the simulation 62.  In 
Figure 5, the apo RdRp presented with an overall higher residual fluctuation (8.97 Å) when compared 
to the bound system (8.47 Å). This degree of high flexibility is concurrent with literature whereby this 
property enables the enzyme to accept single-stranded RNA templates, in doing so; the enzyme can 
effectively propagate viral replication. This finding strongly indicates that binding of compound 47 to 
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the RdRp, in effect, lowered dynamic residual fluctuations of the enzyme thus inducing stability of the 
bound state. 
  
To effectively understand a protein’s function at an atomic perspective, experimental analysis of the 
structure is required. It is important to note that the functional properties of a protein are determined not 
only by its relative structural rigidity but also by its dynamic behaviors 63 64. The binding site residues 
of compound 47 within 5Å: Arg158, Phe193, Pro197, Arg200, Asn316, Asp318, Asp319, Thr364, 
Ser365, Ser367, Ser368, Leu384, Arg386, Arg399, Ser407, Gly410, Asn411, Met414, Tyr415, Gln446, 
Ile447, Tyr448, Gly449, Ala450, Tyr555 and Ser556. Compound 47 is bound covalently to Cys366 
located in the palm domain of the RdRp within the active binding site. In Figure 5, close observation 
revealed that the unbound RdRp experienced a great degree of flexibility as regions assume differing 
conformations in accordance with opening and closing of the active binding site. Upon binding of 
compound 47, the residual fluctuations of RdRp are lowered and regions greatly affected by the covalent 
binding encompass residues 12-46, 443-455 and 530-561. During the 200ns MD simulation, the 
covalently bound system did experience instances of elevated C-α fluctuations. The regions with the 
most notable fluctuations were residues 59-79, 208-219, 232-256 and 305-331 (Figure 5, highlighted in 
blue). This is owed to RdRp undergoing conformational adjustments in order to accommodate 
compound 47 binding and subsequent ligand-enzyme interactions. In essence, compound 47 caused a 
certain degree of interference with the enzyme’s conformation, which is dire for optimum enzyme 
functionalities, leading to interruptions in or possibly extermination of downstream activities important 
in viral replication 8,16. 
 
To provide further insight into the impact of compound 47 binding on conformational sampling, 
template channel width (TCW) and interdomain angles were investigated. Narrower widths and smaller 
angles correspond to a more closed enzyme conformation 65. In Figure 6A and B, we observed that the 
apo system displayed an average interdomain angle of 58.92° and experienced fluctuations in TCW 
ranging between 28.15Å and 39.55Å. Contrastingly, the covalently bound system exhibited a more 
compact structure with an average interdomain angle of 53.92° and a narrower TCW range of 33.39Å- 
39.19Å. Overall, compound 47 binding limits conformational sampling of HCV RdRp, shifting the 
enzyme to a more stabilized closed conformation. Compound 47 allowed the thumb and finger 
subdomains to come into proximity to one another thereby decreasing the width of the template channel, 
subsequently altering the interdomain angle. In doing so, this creates a difficult task for the RNA 
template to gain access to the template channel and the active binding site 66. Based on these findings, 
it is believed that compound 47 prevents the transitions between closed and open conformations, which 
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is imperative for RdRp functioning in replication, leading to inadequate and inefficient execution of 
RNA elongation and subsequent viral replication 7,67. 
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Figure 6: Distance analysis demonstrating the conformational changes of the TCW and interdomain 
angle upon compound 47 binding. (A) Interdomain angle was computed by measuring the angle 
between the centre of masses of the finger, thumb and palm domains. (B) The width is calculated by 
measuring the distance between the C-α atoms of residues Met139 and Val405. (C) Structural dynamic 
movements of the TCW in the apo (purple) and bound (orange, ligand highlighted in green) states of 
HCV RdRp throughout a 200ns molecular dynamics simulation. The dashed line in the highlighted 
images represents the distance between the C-α atoms of the two residues. 
115 
 
To determine the occurrence of correlated dynamics, DCCM analysis was performed. This method 
computes the position of the C-α atoms throughout each independent 200ns MD simulation 68.  The 
colours red to yellow designates highly positive correlated C-α movements. Contrastingly, negative or 
anti-correlated movements are represented as colours blue to black. While similar correlated motions 
occur in both cases, the apo enzyme shows higher levels of correlation (red region), further justified by 
observing a higher occupancy of positive cross-correlation coefficient, as depicted in Figure 7A. This 
correlation, decreases upon ligand binding (Figure 7B), suggesting selective covalent inhibitor, 
compound 47, induces a reduction in fluctuations of RdRp C-α atoms. Residues 246-282 and 380-550 
which correspond to the finger and thumb domains, respectively, displayed anti-correlated movement 
(dark blue region) in the apo and to a slightly lesser degree in the bound system, supporting the residue 
fluctuations in Figure 5.  These domain motions serve fundamental importance as it facilitates RdRp 
closed “active” conformation, which allow for de novo synthesis of RNA. Therefore reduction when 
compound 47 is bound would be consistent with the inability of the enzyme to efficiently execute viral 
replication as the RdRp will not be adequately equipped to accept and bind RNA template thus 
hindering the process of viral replication7.   
 
Figure 7: Dynamical cross-correlation matrix presenting correlation of residues in the apo (A) and 
compound 47-bound system (B). The status of correlated motions is deduced by the colour scale on the 
right, the black cross indicates Cys366 to which compound 47 is covalently bound. 
 
3.3 Solvent Accessible Surface Area and Radius of Gyration  
To further clarify the impact of compound 47 binding on the structure of RdRp, the solvent accessible 
surface area (SASA) was evaluated. Solvent accessibility quantifies the area of a protein obtainable by 
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or exposed to solvent molecules 69,70 . SASA analysis of both systems were conducted and the results 
obtained were presented in Figure 8 (A).   
 
 
Figure 8: (A) Solvent accessible surface area of apo and compound 47 bound RdRp. (B) Radius of 
gyration of both systems were measured over a 200ns simulation. Data obtained was represented as a 
plot displaying the differences arising in radius deviation between the apo and covalent systems.  
 
The results indicate that the apo system maintained a consistent residual exposure to solvents throughout 
the 200ns MD simulation. Contrastingly, the bound system exhibited a progressive decline in the area 
accessible to solvents upon ligand binding. This may serve as an indication that following compound 
47 binding to the RdRp, structural integrity of the protein was compromised. The active site residues 
underwent restructuring, in the process diminishing the area of which was exposed to solvents.  
Consequently, these actions may result in the functional loss of proper enzyme activity 71. The radius 
of gyration (RoG) measures the compactness of a protein whilst concurrently providing insight into the 
biological system’s stability 46,72,73. The comparative RoG for the apo and bound systems is represented 
in Figure 8 (B).  From the relevant figure, it is observed that the RoG value for both the apo and bound 
systems are fairly similar, with an average value of 24.55Å and 24.28Å, respectively.  These findings 
suggest that compound 47 binding to RdRp Cys366 induced a conformational shift to a more compact 
structure, despite only a 0.27Å change, ultimately forming a relatively stable enzyme.  
 
3.4 Ligand interaction with HCV NS5B RdRp 
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Selective covalent inhibition disrupts atomic backbone dynamics of the RdRp through trepidation of 
regulatory elements such as the thumb domain, β-loop and the C-terminal tail. Normal physiological 
structure-based dynamics of the enzyme requires these imperative modulatory components for efficient 
viral transcription and replication. As observed in Figure 9, the indole core (C8H7N) of the inhibitor as 
well as the C-3 pyridone ring are in close contact with Met414. Generally, the active site adopts a 
favourable morphology to allow influential elements such as the β-loop, a component vital for de novo 
initiation, to swing away from the active site thereby sanctioning elongation of the RNA product. Upon 
compound 47 binding, the C-3 pyridone ring of the inhibitor forms three hydrogen interactions with the 
backbone of β-loop residues Gln446, Tyr448 and Gly449. These bond interactions induce the descent 
of the β-loop further into the palm site thereby disrupting the structural conformation of RdRp, giving 
rise to loss of structural integrity. Ultimately, these consequences may result in the overall impediment 
of RdRp enzymatic activity 74.   
 
Figure 9: Ligand-residue interaction diagram of compound, 47 inside the active site of the palm domain 
of the RdRp. Orange dashed lines denote hydrogen bond interactions.   
 
3.5 Free Binding Energy Calculations 
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The Molecular Mechanics/Generalized-Born Surface Area (MM/GBSA) method is extensively utilised 
to approximate the BFE of an inhibitor at an atomic level 75. The MM/GBSA method was used to 
evaluate the total binding energy contributions of compound 47 to the RdRp as presented in Table 1.  
Table 1: Summary of MM/GBSA-based binding free energy contributions to the compound 47- HCV 
RdRp complex 
 
                         Energy components (kcal.mol-1) 
 ∆EVDW ∆Eelec ∆Ggas ∆Gsolv ∆Gbind 
HCV RdRp -4537.81 ± 
26.86 
-35 742.39 
± 139.77 
-4144.35 ± 
146.43 
-7040.47 ± 
115.57 
-11 184.82 
± 79.80 
Compound 47 -7.30 ± 2.0 -9.39 ± 2.45 78.08 ± 
6.48 
-37.53 ± 
1.20 
40.55 ± 
6.36 
Complex -47.77 ± 
2.92  
-160.62 ± 
7.68 
-129.92 ± 
8.14 
60.94 ± 
5.92   
-68.98 ± 
4.55  
∆E
VDW 
: van der Waal; ∆E
elec
: electrostatic; ∆G
gas 
: gas phase interaction; ∆G
solv 
: solvation free energy; 
∆G
bind
: calculated total free binding energy 
 
The calculated free binding energies provide inclusive evidence at a molecular perspective. This 
technique delivers beneficial data to lay groundwork that can propel the design and discovery of small 
inhibitory molecules that possess enhanced ligand binding properties. The calculations are dynamic, 
inexpensive and can be conducted by members of the scientific community as the process is 
programmed using an external interface server and required software is easily accessible online.  The 
calculated free binding energy of the compound 47 and RdRp system was -68.98 kcal.mol-1. Interaction 
forces such as van der Waals (-47.77 ± 2.92 kcal.mol-1) and electrostatic (-160.62 ± 7.68 kcal.mol-1) 
vastly contribute toward the total binding energy of compound 47 to RdRp. Hydrophobic residues lining 
the binding site pocket contributes significantly to the covalently bound systems free binding energy. 
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3.6 Per-residue Interaction Energy Decomposition Analysis  
The total BFE for compound 47 was decomposed into individual residue-based contributions using the 
MM/GBSA approach. The van der Waals (vdW) and electrostatic (elec) interaction contributions 
relative to BFE of compound 47 to RdRp was estimated to acquire perspective into which residue and 
energy constituents had an overall greater impact on the total binding energy (Total). Per-residue energy 
decomposition analysis was executed and presented as Figure 10.  
 
 
Figure 10: The per-residue energy decomposition analysis of compound 47 bound HCV RdRp.  
 
Intermolecular interactions between the residues of the active site facilitate the binding and stabilisation 
of compound 47 in the hydrophobic pocket of RdRp. As observed in figure 10, residues that contributes 
the most energy toward the complex include Arg158 (-3.02 kcal.mol-1 [elec]), Asp319 (-4.125 kcal.mol-
1 [elec]), Gln446 (-5.51 kcal.mol-1 [elec]), Tyr448 (-2.35 kcal.mol-1 [vdW]; -1.96 kcal.mol-1 [elec]) and 
Gly449 (-3.37 kcal.mol-1 [elec]). While the binding site residues that contributed less energy towards 
the complex were: Phe193 (-1.35 kcal.mol-1 [vdw]; 0.10 kcal.mol-1 [elec])), Arg200 (-1.08 kcal.mol-1 
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[vdW]; 1.08 kcal.mol-1 [elec]), Asp318 (-1.64 kcal.mol-1 [vdW]; -1.23 kcal.mol-1 [elec]), Ser368 (-0.96 
kcal.mol-1 [vdW]; -0.83 kcal.mol-1 [elec]), and Met414 (-1.68 kcal.mol-1 [vdW]; -0.33 kcal.mol-1 [elec]). 
From Figure 10, it can be deduced that electrostatic interactions from residues 158, 319, 446, 449 and 
van der Waals interactions from 448 and 414 attributed to the high-energy interaction of the covalent 
system (ΔGBind: -68.98 kcal.mol-1).  
 
4 Conclusion 
The HCV RdRp has a pivotal role as the driving force behind viral transcription and replication. Current 
market-available drugs exhibit rigid pharmacodynamic profiles that require optimization for efficient 
viral inhibition in a safe yet effective manner. The conceptualization of selective covalent inhibition 
brought a new-targeted approach to HCV antiviral therapeutics. Compound 47, an indole core small 
inhibitor, binds covalently to Cys366 of the RdRp.  The consequential shift in conformation prompted 
by selective covalent binding was led by modifications in enzyme flexibility, correlated dynamics and 
intermolecular bonding. Taken together, dynamic and structural effects of compound 47 binding 
disseminate throughout the RdRp, affecting structural integrity of the enzyme. This may lead to the loss 
of appropriate RdRp functioning, ultimately preventing viral replication and propagation. Therefore, it 
can be concluded that selective covalent inhibition is a promising approach that has the potential to 
facilitate future potent anti-HCV therapeutic strategies. 
 
Acknowledgements 
Authors acknowledge the German Academic Exchange Service (DAAD) and the National Research 
Foundation (NRF) and The Centre of High Performance Computing (CHPC,www.chpc.ac.za), Cape 
Town, RSA, for computational resources. 
Conflict of Interest 
Authors declare no potential conflicts of interest.
121 
 
References 
 
1 T. Kazakov, F. Yang, H. N. Ramanathan, A. Kohlway, M. S. Diamond and B. D. Lindenbach, 
PLoS Pathog., 2015, 11, e1004817. 
2 Q. L. Choo, G. Kuo, A. J. Weiner, L. R. Overby, D. W. Bradley and M. Houghton, Science (80-
. )., 1989, 244, 359–362. 
3 M. J. Karoney, A. M. Siika and M. J. Karoney, Pan African Med. Journal. Pan African Med. 
J., 2013, 141444, 44–1937. 
4 K. H. Barakat, J. Law, A. Prunotto, W. C. Magee, D. H. Evans, D. L. Tyrrell, J. Tuszynski and 
M. Houghton, J. Chem. Inf. Model., 2013, 53, 3031–3043. 
5 S. Sun, V. B. Rao and M. G. Rossmann, Curr. Opin. Struct. Biol., 2010, 20, 114–120. 
6 K. X. Chen, C. A. Lesburg, B. Vibulbhan, W. Yang, T. Y. Chan, S. Venkatraman, F. Velazquez, 
Q. Zeng, F. Bennett, G. N. Anilkumar, J. Duca, Y. Jiang, P. Pinto, L. Wang, Y. Huang, O. 
Selyutin, S. Gavalas, H. Pu, S. Agrawal, B. Feld, H. C. Huang, C. Li, K. C. Cheng, N. Y. Shih, 
J. A. Kozlowski, S. B. Rosenblum and F. G. Njoroge, J. Med. Chem., 2012, 55, 2089–2101. 
7 A. A. Eltahla, E. Tay, M. W. Douglas and P. A. White, Antimicrob Agents Chemother, 2014, 
58, 7215–7224. 
8 E. Sesmero and I. F. Thorpe, Viruses, 2015, 7, 3974–3994. 
9 Y. Wei, J. Li, J. Qing, M. Huang, M. Wu, F. Gao, D. Li, Z. Hong, L. Kong, W. Huang and J. 
Lin, PLoS One, 2016, 11, e0148181. 
10 M. L. Barreca, N. Iraci, G. Manfroni and V. Cecchetti, Future Med. Chem., 2011, 3, 1027–
1055. 
11 K. X. Chen, B. Vibulbhan, W. Yang, M. Sannigrahi, F. Velazquez, T. Y. Chan, S. Venkatraman, 
G. N. Anilkumar, Q. Zeng, F. Bennet, Y. Jiang, C. A. Lesburg, J. Duca, P. Pinto, S. Gavalas, 
Y. Huang, W. Wu, O. Selyutin, S. Agrawal, B. Feld, H. C. Huang, C. Li, K. C. Cheng, N. Y. 
Shih, J. A. Kozlowski, S. B. Rosenblum and F. G. Njoroge, J. Med. Chem., 2012, 55, 754–765. 
12 C. B. Dousson, Antivir. Chem. Chemother., 2018, 26, 204020661875643. 
13 E. Lawitz, M. Buti, J. M. Vierling, P. L. Almasio, S. Bruno, P. J. Ruane, T. I. Hassanein, B. 
Muellhaupt, B. Pearlman, L. Jancoriene, W. Gao, H. C. Huang, A. Shepherd, B. Tannenbaum, 
D. Fernsler, J. J. Li, A. Grandhi, H. Liu, F. H. Su, S. Wan, F. J. Dutko, B. Y. T. Nguyen, J. 
122 
 
Wahl, M. N. Robertson, E. Barr, W. W. Yeh, R. M. Plank, J. R. Butterton and E. M. Yoshida, 
Lancet Gastroenterol. Hepatol., 2017, 2, 814–823. 
14 D. Wyles, H. Wedemeyer, Z. Ben-Ari, E. J. Gane, J. B. Hansen, I. M. Jacobson, A. L. Laursen, 
A. Luetkemeyer, R. Nahass, S. Pianko, S. Zeuzem, P. Jumes, H. C. Huang, J. Butterton, M. 
Robertson, J. Wahl, E. Barr, H. K. Joeng, E. Martin and L. Serfaty, Hepatology, 2017, 66, 
1794–1804. 
15 B. Devogelaere, J. M. Berke, L. Vijgen, P. Dehertogh, E. Fransen, E. Cleiren, L. Van Der Helm, 
O. Nyanguile, A. Tahri, K. Amssoms, O. Lenz, M. D. Cummings, R. F. Clayton, S. Vendeville, 
P. Raboisson, K. A. Simmen, G. C. Fanning and T. I. Lin, Antimicrob. Agents Chemother., 
2012, 56, 4676–4684. 
16 A. A. Eltahla, F. Luciani, P. A. White, A. R. Lloyd and R. A. Bull, Viruses, 2015, 7, 5206–
5224. 
17 J. Li, X. Liu, S. Li, Y. Wang, N. Zhou, C. Luo, X. Luo, M. Zheng, H. Jiang and K. Chen, Int. 
J. Mol. Sci., 2013, 14, 22845–22856. 
18 I. Buxton and L. Benet, Goodman Gilman’s Pharmacol. Basis Ther., 2011, 17–39. 
19 K. Kumthip and N. Maneekarn, Virol. J., 2015, 12, 1–12. 
20 N. Echeverria, G. Moratorio, J. Cristina and P. Moreno, World J. Hepatol., 2015, 7, 831–845. 
21 S. Fonseca-Coronado, A. Escobar-Gutiérrez, K. Ruiz-Tovar, M. Y. Cruz-Rivera, P. Rivera-
Osorio, M. Vazquez-Pichardo, J. C. Carpio-Pedroza, J. A. Ruíz-Pacheco, F. Cazares and G. 
Vaughan, J. Clin. Microbiol., 2012, 50, 281–287. 
22 D. S. Johnson, E. Weerapana and B. F. Cravatt, Future Med. Chem., 2010, 2, 949–964. 
23 R. A. Bauer, Drug Discov. Today, 2015, 20, 1061–1073. 
24 G. Lee, D. E. Piper, Z. Wang, J. Anzola, J. Powers, N. Walker and Y. Li, J. Mol. Biol., 2006, 
357, 1051–1057. 
25 M. Hagel, D. Niu, T. St Martin, M. P. Sheets, L. Qiao, H. Bernard, R. M. Karp, Z. Zhu, M. T. 
Labenski, P. Chaturvedi, M. Nacht, W. F. Westlin, R. C. Petter and J. Singh, Nat. Chem. Biol., 
2011, 7, 22–24. 
26 K. K. Hallenbeck, D. M. Turner, A. R. Renslo and M. R. Arkin, Curr. Top. Med. Chem., 2017, 
17, 4–15. 
27 H. McWilliam, W. Li, M. Uludag, S. Squizzato, Y. M. Park, N. Buso, A. P. Cowley and R. 
Lopez, Nucleic Acids Res., 2013, 41, W597–W600. 
123 
 
28 A. Bateman, M. J. Martin, C. O’Donovan, M. Magrane, E. Alpi, R. Antunes, B. Bely, M. 
Bingley, C. Bonilla, R. Britto, B. Bursteinas, H. Bye-AJee, A. Cowley, A. Da Silva, M. De 
Giorgi, T. Dogan, F. Fazzini, L. G. Castro, L. Figueira, P. Garmiri, G. Georghiou, D. Gonzalez, 
E. Hatton-Ellis, W. Li, W. Liu, R. Lopez, J. Luo, Y. Lussi, A. MacDougall, A. Nightingale, B. 
Palka, K. Pichler, D. Poggioli, S. Pundir, L. Pureza, G. Qi, S. Rosanoff, R. Saidi, T. Sawford, 
A. Shypitsyna, E. Speretta, E. Turner, N. Tyagi, V. Volynkin, T. Wardell, K. Warner, X. 
Watkins, R. Zaru, H. Zellner, I. Xenarios, L. Bougueleret, A. Bridge, S. Poux, N. Redaschi, L. 
Aimo, G. ArgoudPuy, A. Auchincloss, K. Axelsen, P. Bansal, D. Baratin, M. C. Blatter, B. 
Boeckmann, J. Bolleman, E. Boutet, L. Breuza, C. Casal-Casas, E. De Castro, E. Coudert, B. 
Cuche, M. Doche, D. Dornevil, S. Duvaud, A. Estreicher, L. Famiglietti, M. Feuermann, E. 
Gasteiger, S. Gehant, V. Gerritsen, A. Gos, N. Gruaz-Gumowski, U. Hinz, C. Hulo, F. Jungo, 
G. Keller, V. Lara, P. Lemercier, D. Lieberherr, T. Lombardot, X. Martin, P. Masson, A. 
Morgat, T. Neto, N. Nouspikel, S. Paesano, I. Pedruzzi, S. Pilbout, M. Pozzato, M. Pruess, C. 
Rivoire, B. Roechert, M. Schneider, C. Sigrist, K. Sonesson, S. Staehli, A. Stutz, S. Sundaram, 
M. Tognolli, L. Verbregue, A. L. Veuthey, C. H. Wu, C. N. Arighi, L. Arminski, C. Chen, Y. 
Chen, J. S. Garavelli, H. Huang, K. Laiho, P. McGarvey, D. A. Natale, K. Ross, C. R. Vinayaka, 
Q. Wang, Y. Wang, L. S. Yeh and J. Zhang, Nucleic Acids Res., 2017, 45, D158–D169. 
29 J. de Vicente, R. T. Hendricks, D. B. Smith, J. B. Fell, J. Fischer, S. R. Spencer, P. J. Stengel, 
P. Mohr, J. E. Robinson, J. F. Blake, R. K. Hilgenkamp, C. Yee, G. Adjabeng, T. R. Elworthy, 
J. Li, B. Wang, J. T. Bamberg, S. F. Harris, A. Wong, V. J. P. Leveque, I. Najera, S. Le Pogam, 
S. Rajyaguru, G. Ao-Ieong, L. Alexandrova, S. Larrabee, M. Brandl, A. Briggs, S. Sukhtankar 
and R. Farrell, Bioorganic Med. Chem. Lett., 2009, 19, 5652–5656. 
30 J. Bhachoo and T. Beuming, in Methods in Molecular Biology, 2017, vol. 1561, pp. 235–254. 
31 G. Madhavi Sastry, M. Adzhigirey, T. Day, R. Annabhimoju and W. Sherman, J. Comput. 
Aided. Mol. Des., 2013, 27, 221–234. 
32 Z. Yang, K. Lasker, D. Schneidman-Duhovny, B. Webb, C. C. Huang, E. F. Pettersen, T. D. 
Goddard, E. C. Meng, A. Sali and T. E. Ferrin, J. Struct. Biol., 2012, 179, 269–278. 
33 O. Trott and A. J. Olson, J. Comput. Chem., 2010, 31, 455–61. 
34 E. F. Pettersen, T. D. Goddard, C. C. Huang, G. S. Couch, D. M. Greenblatt, E. C. Meng and 
T. E. Ferrin, J. Comput. Chem., 2004, 25, 1605–1612. 
35 F. Fogolari, A. Corazza, S. Toppo, S. C. E. Tosatto, P. Viglino, F. Ursini and G. Esposito, J. 
Biomed. Biotechnol., 2012, 2012, 303190. 
124 
 
36 D. a. Case, I. T.E. Cheatham, T. Darden, H. Gohlke, R. Luo, J. K.M. Merz,  a. Onufriev, C. 
Simmerling, B. Wang and R. Woods., J. Comput. Chem, 2005, 26, 1668–1688. 
37 R. Salomon-Ferrer, D. A. Case and R. C. Walker, Wiley Interdiscip. Rev. Comput. Mol. Sci., 
2013, 3, 198–210. 
38 P. Ramharack, S. Oguntade and M. E. S. Soliman, RSC Adv., 2017, 7, 22133–22144. 
39 S. Khan, I. Bjij, R. M. Betz and M. E. S. Soliman, Future Med. Chem., 2018, 10, 1003–1015. 
40 S. Khan, I. Bjij, F. Oluto and M. E. S. Soliman, Future Med. Chem., 2018, 10, 2265–2275. 
41 R. Betz, Dabble, https://dabble.robinbetz.com/, 2017 
42 N. N. Mhlongo, M. Ebrahim, A. A. Skelton, H. G. Kruger, I. H. Williams and M. E. S. Soliman, 
RSC Adv., 2015, 5, 82381–82394. 
43 P. Gonnet, J. Comput. Phys., 2007, 220, 740–750. 
44 W. Humphrey, A. Dalke and K. Schulten, J. Mol. Graph., 1996, 14, 33–38. 
45 A. Bornot, C. Etchebest and A. G. De Brevern, Proteins Struct. Funct. Bioinforma., 2011, 79, 
839–852. 
46 M. I. Lobanov, N. S. Bogatyreva and O. V Galzitskaia, Mol. Biol. (Mosk)., 2008, 42, 701–706. 
47 V. Gapsys, S. Michielssens, J. H. Peters, B. L. de Groot and H. Leonov, Methods Mol. Biol., 
2015, 1215, 173–209. 
48 M. Schauperl, P. Czodrowski, J. E. Fuchs, R. G. Huber, B. J. Waldner, M. Podewitz, C. Kramer 
and K. R. Liedl, J. Chem. Inf. Model., 2017, 57, 345–354. 
49 C. Agoni, P. Ramharack and M. E. S. Soliman, Future Med. Chem., 2018, 10, 1665–1675. 
50 J. M. Hayes and G. Archontis, in Molecular Dynamics – Studies of Synthetic and Biological 
Macromolecules, 2011. 
51 T. Hou, J. Wang, Y. Li and W. Wang, J. Chem. Inf. Model., 2011, 51, 69–82. 
52 X. Zhang, H. Perez-Sanchez and F. C. Lightstone, Curr. Top. Med. Chem., 2017, 17, 1631–
1639. 
53 B. R. Miller, T. D. McGee, J. M. Swails, N. Homeyer, H. Gohlke and A. E. Roitberg, J. Chem. 
Theory Comput., 2012, 8, 3314–3321. 
54 N. Singh and A. Warshel, Proteins Struct. Funct. Bioinforma., 2010, 78, 1705–1723. 
55 P. Ramharack and M. E. S. Soliman, J. Biomol. Struct. Dyn., 2018, 36, 1118–1133. 
125 
 
56 K. E. Machaba, N. N. Mhlongo, Y. M. Dokurugu and M. E. S. Soliman, Future Med. Chem., 
2017, 9, 1055–1071. 
57 U. Ndagi, N. N. Mhlongo and M. E. Soliman, Mol. BioSyst., 2017, 13, 1157–1171. 
58 S. Oguntade, P. Ramharack and M. E. Soliman, Future Virol., 2017, 12, 261–273. 
59 P. Appiah-Kubi and M. E. S. Soliman, J. Biomol. Struct. Dyn., 2016, 34, 2418–2433. 
60 R. Galindo-Murillo, D. R. Roe and T. E. Cheatham, Biochim. Biophys. Acta - Gen. Subj., 2015, 
1850, 1041–1058. 
61 B. Hess, Phys. Rev. E - Stat. Physics, Plasmas, Fluids, Relat. Interdiscip. Top., 2002, 65, 031910. 
62 C. V. Kumar, R. G. Swetha, A. Anbarasu and S. Ramaiah, Adv. Bioinformatics, 2014, 2014, 1–
10. 
63 K. Henzler-Wildman and D. Kern, Nature, 2007, 450, 964–972. 
64 L. Q. Yang, P. Sang, Y. Tao, Y. X. Fu, K. Q. Zhang, Y. H. Xie and S. Q. Liu, J. Biomol. Struct. 
Dyn., 2014, 32, 372–393. 
65 B. C. Davis, J. A. Brown and I. F. Thorpe, Biophys. J., 2015, 108, 1785–1795. 
66 B. C. Davis, J. A. Brown and I. F. Thorpe, Biophys. J., 2015, 108, 1785–1795. 
67 J. A. Brown and I. F. Thorpe, Biochemistry, 2015, 54, 4131–4141. 
68 U. Ndagi, N. N. Mhlongo and M. E. Soliman, Mol. BioSyst., 2017, 13, 1157–1171. 
69 T. J. Richmond, J. Mol. Biol., 1984, 178, 63–89. 
70 L. McGillewie and M. E. Soliman, Mol. Biosyst., 2016, 12, 1457–1467. 
71 S. E. Boyce, N. Tirunagari, A. Niedziela-Majka, J. Perry, M. Wong, E. Kan, L. Lagpacan, O. 
Barauskas, M. Hung, M. Fenaux, T. Appleby, W. J. Watkins, U. Schmitz and R. Sakowicz, PLoS 
One, 2014, 9, e84808. 
72 T. Sindhu and P. Srinivasan, RSC Adv., 2015, 5, 14202–14213. 
73 L. McGillewie and M. E. Soliman, Mol. Biosyst., 2016, 12, 1457–1467. 
74 J. Li and K. A. Johnson, J. Biol. Chem., 2016, 291, 10067–10077. 
75 S. Genheden and U. Ryde, Expert Opin. Drug Discov., 2015, 10, 449–461. 
126 
 
CHAPTER 6 
 
 
Enhanced Pharmacophore-based Virtual Screening Approach in the Discovery of 
Potential Inhibitors of HCV NS3 Helicase 
 
Letitia Shunmugama, Nikita Devnaraina and Mahmoud E. S. Solimana* 
 
a Molecular Bio-Computation and Drug Design laboratory, School of Health Sciences, University of 
KwaZulu-Natal, Westville Campus, Durban 4001, South Africa. 
*Corresponding Author: Mahmoud E.S. Soliman 
School of Health Sciences, University of KwaZulu-Natal, Westville Campus, Durban 4001, South 
Africa 
Email: soliman@ukzn.ac.za 
Telephone: +27 (0) 31 260 7413, Fax: +27 (0) 31 260 7872 
 
  
127 
 
Abstract 
The helicase is essential in the modulation of Hepatitis C virus (HCV) life cycle, hence a good target 
for drug design, a domain highly neglected in literature. Quercetin is an inhibitor of several viruses, 
including flaviviruses. However due to its compromised pharmacodynamics, development of new 
potent helicase inhibitors that address challenges in antiviral therapies are crucial. Herein, an in-house 
pharmacophore-based virtual screening protocol was applied to identify improved potential inhibitors 
based on highly contributing residues that bind with highest affinity to quercetin. This is a preliminary 
investigation to initiate wider-spectrum screening of potential helicase inhibitors and can be 
implemented in rational drug design of anti-HCV drugs and other viruses. Further computational and 
experimental work are advised to validate this approach. 
 
Keywords 
Hepatitis C virus, drug discovery; NS3 helicase potential inhibitors; per-residue energy decomposition-
based pharmacophore; virtual screening. 
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1. Introduction 
Hepatitis C virus (HCV) is the causative agent of hepatitis C infection [1]. Identified as a hepatropic 
single-stranded RNA virus, HCV is a member of  the  Flaviviridae family from the Hepacivirus genus 
[2] . The virus leads to major hepatic-related disorders such as cirrhosis, fibrosis and hepatocellular 
carcinomas, resulting in severe liver damage and in some cases, death [3]. The World Health 
Organization (WHO) has estimated that approximately 170-185 million people are affected by HCV 
throughout the world and is fast becoming a global pandemic [4].  
 
Drug development industries have focused intensively on viral enzymes as possible therapeutic targets 
based on their important roles in the viral life cycle [5]. One of the most significant HCV enzymes is 
the non-structural protein 3 (NS3), which consists of the RNA helicase, non-structural protein 4A 
(NS4A) co-factor and serine protease [6–8]. At present, few NS3 protease inhibitors have been 
approved by the Food and Drug Administration (FDA), such as telaprevir [9], boceprevir [10], 
simeprevir [11], elbasvir/grazoprevir [12] and danoprevir [13]. Although the NS3 protease serves as a 
prevalent target in antiviral therapy, drug resistance and system toxicity has created an ever-escalating 
obstacle in drug development, consequently igniting the need to explore and discover novel inhibitors 
against HCV [14].  
The NS3 helicase is often a neglected aspect of the NS3 enzyme complex as most attention is directed 
toward the protease. In the HCV life cycle, the helicase plays a vital role in the execution of genomic 
replication and appropriate viral assembly [8], Helicases are described as small molecular motors driven 
by the hydrolysis of adenosine triphosphate (ATP), a process that allows the helicase to grasp a single 
RNA or DNA strand, causing dissociation from its complementary strand. The RNA helicase is an 
essential requirement for cell transcription, translation, and RNA splicing [15], thus rendering the 
protein an attractive candidate for drug target studies [8,16]. 
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Figure 1: Three-dimensional structure of NS3 protein complex (PDB: 3O8D). The ATP-
binding domain (highlight in red) is the region in which ATP or Quercetin can effectively bind.  
 
Quercetin is a natural flavonoid compound found in most vegetables and fruits [17]. The flavonoid has 
been identified as a competitive inhibitor of adenosine triphosphate (ATP) at the relative binding site 
located within the viral RNA helicase (Figure 1). This phenomena was successfully observed in 
flavivirus such as Dengue fever as well as HCV [16,18]. The therapeutic utilization of quercetin faces 
major difficulties; the compound is relatively unstable within a physiological intermediate and has poor 
solubility, thus limiting its application solely to oral administration [19]. For these reasons, it would be 
highly beneficial to discover potential compounds that can inhibit ATP binding with similar moieties, 
improved pharmacodynamic profiles, higher potency and restricted adverse effects. 
 
Over the years, computer-aided drug design (CADD) methods have greatly contributed toward the 
design and development of drugs against a wide diversity of ailments, viruses and bacteria [20]. 
Computational practices are often utilized to accelerate the discovery  process and direct attention 
toward compounds that exhibit potential antiviral activities, elaborate on enzyme-drug interactions and 
provide improvements for promising compounds [21,22].  
 
Virtual screening (VS) is a process that uses a sequence of computational tools to search through 
compound libraries or databases for small molecules with similar structures to the template scaffold. 
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The structures found through VS should bind to the amino acid residues within the active site of the 
target [23–26]. Structure-based VS screens for potential ligands based on the 3D-structure of an 
enzyme’s active binding pocket. Contrastingly, pharmacophore or ligand-based VS searches for 
favorable, similar features of ligands with known bioactive properties for pharmacophore model 
generation [27]. The latter approach is based on intermolecular interactions that include hydrogen 
bonding, electrostatic energies and charge. This approach also screens for potential compounds that 
form interactions with highly contributing residues based on the binding free energy (BFE) [28].  
 
Herein, we implemented molecular dynamics (MD) simulations, pharmacophore-based VS and per-
residue energy decomposition (PRED) analysis for residues that contribute the most to free binding 
energy, to enhance the precision of the pharmacophore model. The pharmacophoric approach followed 
in this study can be implemented by medicinal chemists in the drug discovery process for potent 
inhibitors against HCV. 
 
2. Computational Methodology 
 
 
Figure 2. The systematic workflow applied in this study. 
 
2.1 Receptor and Ligand Preparation 
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The HCV NS3 helicase-protease complex was obtained from RSCB Protein Data Bank (PDB code: 
3O8D) [29]. The 3D-structure of quercetin was created using Avogadro [30]. The helicase and ligands 
were prepared using UCSF Chimera software [31].  
 
2.2 Molecular Docking 
The compounds were docked into the ATPase pocket of the HCV NS3 helicase. Through UCSF 
Chimera, using the AutoDock Vina plugin, compounds were docked by means of the grid box function 
to express the binding site (spacing of 0.375 Å; x, y, z dimensions of 14.28 x 22.51 x 18.29) [32,33]. 
The docked results with optimum poses and highest binding affinities to the helicase ATPase pocket 
were selected and thereafter subjected to MD simulations.  
 
2.3 Molecular Dynamics Simulation 
The utilization of MD simulations provides a powerful tool for investigation of the physical activities 
executed by atoms and molecules, thus providing an insight into the biomolecular processes of  target 
systems [34]. The MD simulations were performed using the PMEMD dynamics engine in the 
AMBER14 package with GPU acceleration [35]. The NS3 enzyme was dehydrogenated and 
parameterized using the AMBER FF14SB force field [36]. Hydrogen atoms were added to the ligands 
and charged by means of Gasteiger charges. The antechamber module was utilized to generate partial 
atomic charges for the ligands by applying General Amber Force Field (GAFF) and restrained 
electrostatic potential (RESP) procedures [37]. The LEAP module was applied to neutralise and solvate 
the systems through the addition of hydrogen, sodium and chloride atoms, whilst suspending them in 
an orthorhombic box of TIP3P water molecules so that all atoms were within 10 Å of the box edges. 
The system was initially minimized with the restraint potential of 10 kcal.mol−1 Å−2 for consideration 
of solute molecule of 2 500 steps for 1 000 steepest descent steps, followed by 1000 steps of conjugate 
gradient minimization. Additionally, an unrestrained full minimization of 200 steps was completed by 
conjugate gradient algorithm. A canonical ensemble simulation was performed from 0 to 300 Kelvin 
(K) for 50ps to maintain a fixed volume and number of atoms in each system. Potential harmonic 
restraint of 10 kcal.mol-1 Å2 for solute atoms and Langevin thermostat with collision frequency of 1.0 
ps-1 was applied to each system.  All systems were equilibrated for 500 ps with a constant operating 
temperature of 300 K. The pressure and the number of atoms were kept constant to bear resemblance 
to an isobaric–isothermal ensemble (NPT). The pressure the systems were maintained at 1 bar using the 
Berendsen barostat [38] and the SHAKE algorithm was utilized for hydrogen bond constraint [39,40]. 
 
2.4 Thermodynamic Binding Free Energy Calculations 
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Molecular dynamic simulations allow free energy differences which controls the underlying mechanism 
of all biological processes [41]. Calculations for BFE is a crucial method employed to comprehensively 
observe the binding mechanism between a ligand or compound and enzyme, whilst encompassing both 
enthalpic and enthropic contributions [42]. Estimation of the binding affinity within a docked system is 
calculated through BFE using the Molecular Mechanics/Generalized Born Surface Area (MM/GBSA) 
method. This method provides reproducible relative binding affinities of compounds with great 
accuracy and warrants considerably less computational resources in comparison to a full-scale MD free 
energy perturbation/thermodynamic simulation [43].  In this study, BFE was averaged over 20 000 
snapshots, which were generated from the 200ns trajectory. The explicit solvent employed in the MD 
simulation was removed and substituted with a dielectric continuum as per MM/GBSA protocol [44]. 
Molecular mechanics force fields were employed to calculate energy contributions from the atomic 
coordinates of the ligands, NS3 enzyme and complex in a gas-phase. The equations below elaborate the 
process in which the binding free energies (ΔG) were assessed:  
(1) ∆Gbind = ∆Gcomplex - ∆Greceptor - ∆Gligand 
(2) ∆Gbind = Egas + Gsol – TΔS 
(3) Egas = Eint + Evdw + Eele 
(4) Gsol + GGB + GSA 
(5) GSA + γSASA 
 
Where: ΔGbind is gas-phase summation, gas-phase energy (Egas) and the solvation energy, Gsol, is less 
the entropy (TΔS) term. The Egas is the sum of internal energy, Eint, van der Waals (vdW) energy, EvdW 
and electrostatic energy, Eele. The total solvation energy is calculated by a summation of the total energy 
contributions of polar and non-polar states (GGB and GSA, respectively). The GSA is calculated by means 
of the solvent accessible surface area, generated by water probe radius of 1.4˚A. Resolution of GGB 
equation allows the determination for the energy contributions of polar states. The total entropy of the 
solute is denoted as ‘S’ and temperature as ‘T’. The solute and solvent dielectric constants are set to 1 
and 80, respectively [45,46]. 
 
2.5 Creation of Pharmacophore Model and Library Generation 
Quercetin, the preliminary potential inhibitor was simulated within the ATP-binding pocket for 20ns to 
establish its bound conformation (binding affinity: -8.1 kcal.mol-1). To create a pharmacophore model, 
PRED analysis was used to identify the amino acid residues that greatly contribute toward helicase-
ligand binding and to allow identification of the ligand pharmacophoric moieties that facilitate these 
interactions. The generated model thereafter serves as a chemical scaffold that is used to screen through 
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the ZINC Database via the ZINCPharmer online software [47–49]. The resultant screened compounds 
were filtered based on toxicity and druggability using ADMET properties and Lipinski’s rule of five 
[50–53].  
 
2.6 Structure-based Virtual Screening 
The top hits generated from screening were subsequently docked to distinguish ligands based on 
conformational  features of the molecules that directly influence its binding affinity to the ATPase 
pocket of the helicase [54]. Before docking the ligands, Gasteiger partial chargers were allocated to the 
ligands and atom types were defined using the Autodock Graphical user interface [32]. To assist 
docking compatibility of the ligands, Raccoon software was utilized to convert the files to pdbqt format 
[54]. The Lamarckian genetic algorithm was used to create different docking poses, thereupon 
examined to procure binding affinities (kcal.mol-1 ) [55]. For every ligand, approximately 50 poses were 
considered and the five ligands, which bound the with highest binding affinities to the NS3 helicase 
ATPase pocket were selected. The workflow adapted in this study is represented in Figure 2. 
 
2.7 Validation of Docking Approach 
To validate the docking approach employed in this study, the resultant docked quercetin-helicase 
complex was superimposed onto HCV NS3 helicase protein in complex with a known molecule that 
binds to the ATP-binding site (Figure S1). Molecular docking generates optimal geometric 
conformations of a bound ligand in an active pocket, though brief MD simulations do not ensure 
stability of the complex and bring about disorientation of molecules. Hence, to validate this approach, 
the three most favorable ligands with highest binding affinities bound to the helicase were subjected to 
200ns of MD simulations 
 
3. Results  
3.1 Pharmacophore Model and Virtual Screening 
Over recent years, medicinal chemistry has effectively utilized pharmacophore approaches and is 
considered one of the most successful and useful strategies in rational drug design. In past attempts 
during drug research, the binding affinity data was the main source for establishing energy-based 
pharmacophore; however, flaws such as the emergence of false positives and negatives rendered this 
approach unreliable.  To overcome this problem, the PRED method was employed. The pharmacophoric 
model presented in Figure 3 was used as a 3D structural template to search the ZINCPHARMER 
database, which yielded a total of three hits. The generated library was then docked using Autodock 
Vina with the crystal structure of HCV NS3 helicase (PDB: 3O8D). After screening the library, three 
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compounds with the highest binding affinities were selected from the library (Table 1). Lipinski’s rule 
of five is based on a set of property values such as the number of hydrogen-bond donors and acceptors, 
the molecular weight and the logP, derived from the FDA approved drugs, which are known to have 
clinically acceptable ADME properties. Thus, molecules that pass the Lipinski rule are expected to be 
active in humans after oral administration. It must be noted that all the three hit compounds obeyed 
Lipinski’s rules. The three hit compounds were then subjected to a 200ns MD simulation a studied to 
precisely determine the ligand–receptor models in the state close to realistic conditions and to further 
explore the binding modes of the two inhibitors.  
 
 
Figure 3:  Pharmacophore model generation from quercetin-helicase complex. The highlighted yellow 
regions represent the pharmacophoric moieties that were selected for the model, based on residues that 
contributed the most to the binding affinity. Using ZINCPharmer, three hits were generated from the 
pharmacophore-based virtual screening process. 
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Table 1: The ID codes, docked 3D-structures and Lipinski’s rule of five for the three hits obtained 
through virtual screening using ZINCPharmer [49,56,57]. 
 Hit ID  3D-Structure BA 
(kcal.
mol-1) 
xLogP MW 
(g/mol) 
HBD HBA 
 1 ZINC18022381 
 
-8.7 2.60 392.395 0 9 
 2 ZINC33753131 
 
 
-8.5 5.39 411.485 2 6 
 3 ZINC02495613 
 
-8.4 6.42 395.502 1 3 
BA: Binding affinity;MW: molecular weight; HBD: hydrogen bond donor; HBA : hydrogen bond 
acceptor 
 
3.2 Molecular Dynamic Simulations 
Molecular dynamics simulations of 200ns and MM/GBSA BFE calculations for the three top-ranked 
compounds and Quercetin in complex with NS3 helicase, were conducted to validate the accuracy of 
the binding affinities obtained from the docking calculations. 
136 
 
 
3.3 System Stability  
The stability of Quercetin and the top-ranked systems were assessed by calculating the root-mean-
square deviation (RMSD) for the respective systems. A plot of the RMSD for the simulated systems 
can be found in the supplementary section (Figure S2). All systems reached convergence, which 
validated their stability in the binding site of HCV NS3 helicase.  
 
3.4 Molecular Dynamic Simulations and Free Binding Energy Calculations 
The MM/GBSA method is widely used to estimate the BFE of an inhibitor at an atomic perspective 
[58]. The MM/GBSA method was used to evaluate the total binding energy contributions of quercetin 
and the top hits bound to the NS3 helicase as presented in Table 2.  
 
Table 2: Summary of MM/GBSA-based binding free energy contributions of Quercetin and the top-
ranked compounds with HCV NS3 helicase. 
Energy components (kcal.mol-1) 
 
∆EvdW ∆Eelec ∆Ggas ∆Gsolv ∆Gbind 
Quercetin -33.06 ± 4.03 -8.71 ± 5.78 -41.77 ± 7.40 21.92 ± 4.47 -19.85 ± 4.32 
ZINC18022381 -38.71 ± 3.75 -16.33 ± 5.03 -55.04 ± 6.41 32.88 ± 4.77 -22.15 ± 3.23 
ZINC33753131 -38.51 ± 4.14 -13.30 ± 4.01 -51.82 ± 6.25 26.16 ± 3.15 -25.66 ± 4.59 
ZINC02495613 -36.38 ± 3.31 -17.35 ± 6.13 -53.73 ± 6.72 23.13 ± 3.93 -30.61 ± 4.85 
∆E
VDW 
: van der Waal; ∆E
elec
: electrostatic; ∆G
gas 
: non-polar solvation interaction; ∆G
solv 
: solvation 
free energy; ∆G
bind
: calculated total free binding energy 
 
3.5 Per-residue Energy Decomposition 
The energetics of the top-ranked hits in complex with NS3 helicase was assessed by computing the per-
residue energy contribution to the total BFE of the system. The results obtained are present in Figure 4, 
5 and 6.  
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3.5.1 Binding mode analysis of Hit 1 
The binding interactions of ZINC18022381 and the per-residue energy contributions of active site 
residues are presented in Figure 4.  ZINC18022381 bound to HCV NS3 helicase binding pocket with a 
docking score of -8.7 kcal.mol-1 and exhibited a higher MM/GBSA BFE (-22.15 kcal.mol-1) than 
quercetin (-8.1 kcal.mol-1 and -19.85 kcal.mol-1, respectively).  
 
 
Figure 4: (A) The per-residue energy decomposition analysis and (B) ligand interaction plot of 
ZINC18022381 bound to the ATP-binding site of HCV NS3 helicase. 
 
3.5.3 Binding mode analysis of Hit 2 
The binding interactions of ZINC33753131 and the per-residue energy contributions of active site 
residues are presented in Figure 5.  ZINC33753131 bound to HCV NS3 helicase binding pocket with a 
docking score of -8.5 kcal.mol-1 and exhibited a higher MM/GBSA BFE (-25.66 kcal.mol-1) compared 
to quercetin (-8.1 kcal.mol-1 and -19.85 kcal.mol-1, respectively).  
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Figure 5: (A) The per-residue energy decomposition analysis and (B) ligand interaction plot of 
ZINC33753131 bound to the ATP-binding site of HCV NS3 helicase. 
 
3.5.4 Binding mode analysis of Hit 3 
The binding interactions of ZINC02495613 and the per-residue energy contributions of active site 
residues are presented in Figure 6.  ZINC02495613 bound to HCV NS3 helicase binding pocket with a 
docking score of -8.4 kcal.mol-1 and exhibited the highest MM/GBSA BFE (-30.61 kcal.mol-1) 
compared to quercetin (-8.1 kcal.mol-1 and -19.85 kcal.mol-1, respectively) and the other 
ZINC18022381 and ZINC33753131.  
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Figure 6: (A) The per-residue energy decomposition analysis and (B) ligand interaction plot 
ZINC02495613 bound to the ATP-binding site of HCV NS3 helicase.  
 
4. Discussion 
The highest relative BFE observed in all the systems result from interactions established between the 
ligand within the active site of the helicase. ZINC02495613 (H3) in complex with NS3 helicase 
exhibited the highest BFE (-30.61 kcal.mol-1) in comparison to quercetin (-19.85 kcal.mol-1), 
ZINC18022381 (H1, -22.15 kcal.mol-1) and ZINC33753131 (C3, -25.66 kcal.mol-1), as shown in Table 
2. From the relevant table, the BFE values suggest that ZINC02495613, ZINC33753131 and 
ZINC18022381 are more effective potential inhibitor of HCV NS3 compared to quercetin. 
Intermolecular vdW forces (-36.38 kcal.mol-1), electrostatic interactions (-17.35 kcal.mol-1) and non-
polar solvation interactions (-53.73 kcal.mol-1) contributed largely toward the total binding energy of 
ZINC02495613 to NS3. A polar solvation energy contribution of 23.13 kcal.mol-1 to the total binding 
free energy was observed for the ZINC02495613 system. The hydrophobic residues that line the ATP-
binding site pocket contribute greatly to the free binding energy of each bound system. 
 
The stability of ZINC18022381 in complex with NS3 exhibited an average RMSD of 2.38 Å 
extrapolated from a 200ns MD trajectory (Figure S2). The intermolecular interactions formed between 
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the compound and NS3 binding site residues were examined by calculating the per-residue energy 
contribution to the total BFE. Figure 4 depicts the per-residue contribution and the ligand interaction 
diagram of ZINC18022381 bound to the HCV NS3 helicase. Analysis of per-residue energy 
contribution revealed that significant contributions toward BFE emanated from Tyr255, Thr433, 
Asp435 and Arg481. The binding site residues that contributed the least energy toward the complex 
were: Gly251, Phe252, Val411, Tyr432 and Gly434. The values of per-residue energy contribution are 
found in supplementary, Table S1. The optimum binding conformation adopted by ZINC18022381 was 
most likely due to vdW interactions form Asp435 and Arg481 and electrostatic interaction from Tyr255. 
 
The stability of ZINC33753131 in complex with NS3 exhibited an average RMSD of 2.27 Å 
extrapolated from a 200ns MD trajectory (Figure S2). Figure 5 depicts the per-residue contribution and 
the ligand interaction diagram of ZINC33753131 bound to the HCV NS3 helicase. Analysis of per-
residue energy contribution discovered that the following residues contributed the most to the over BFE 
of the complex: Phe252, Tyr255, Arg481. The binding site residues that contributed minimum energy 
to the total BRE of the complex included: Gly221, Ala248, Gly251, Tyr432, Gly480 and Gly482. The 
values of per-residue energy contribution are found in supplementary, Table S2. Therefore, the optimum 
binding conformation of hit is likely the result of electrostatic energy contribution from Arg481 and 
vdW interactive forces from Tyr255 and Arg481.  
 
The stability of ZINC02495613 in complex with NS3 exhibited an average RMSD of 2.07 Å estimated 
from a 200ns MD trajectory (Figure S2). Figure 6 depicts the per-residue contribution and the ligand 
interaction diagram of ZINC02495613 bound to the HCV NS3 helicase. Analysis of per-residue energy 
contribution discovered that the following residues contributed the most to the overall BFE of the 
complex: Asn349, Gly480, Arg481 and Gly482. The binding site residues that contributed the least 
energy to the total BFE of the complex included: Thr220, Gly221, Thr226, Phe252, Tyr255, His347 
and Thr479.  The binding mode of ZINC02495613 revealed that ZINC02495613 forms H-bonds with 
Gly480 and Gly482. The calculated H-bond distance between the nitrogen atom of Gly480 and the 
oxygen atom of the compound is 2.79 Å while the distance between Gly482 nitrogen atom and the 
compounds oxygen atom is 3.26 Å. Furthermore, the hydrophobic interactions from the surrounding 
residues stabilize the conformation of the ligand in the active site. The values of per-residue energy 
contribution are found in supplementary, Table S3. The formation of hydrogen bonds and generated 
hydrophobic interactions signifies an optimum binding conformation adopted by hit 3 within the active 
site.  
 
5. Conclusion 
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The HCV remains a global threat and requires continuous research toward its prevention and treatment. 
Computational approaches allow an in-depth perspective into the underlying structural and dynamical 
mechanism involved in ligand-enzyme binding, which can be observe at an atomistic level. The 
utilization of computational techniques accelerates the overall process of drug discovery whilst being 
cost-efficient. This study acts as an incentive to initiate broader screening of important molecules as 
HCV helicase inhibitors. The lead compounds identified in this study serve as a promising start for 
larger scale screenings. The techniques employed in this study were selected for its efficiency, 
reliability, and for its capacity to aid effective design for lead optimization and potential drug 
development. The HCV helicase is undoubtedly a very under-developed drug target in literature, 
evident by the considerably large gap in the manner of which computational studies are performed on 
potential inhibitors of the helicase. However, recent advancements in the pharmaceutical industry may 
pave the way for new attempts to discover improved helicase inhibitors.  With continued research and 
on-going advances in this field of study, hopefully the efforts will culminate in the discovery of more 
compounds for the use in clinical trials and laboratory practices. Further research toward understanding 
the structural and dynamic mechanisms of HCV enzymes in their natural biological system would be 
imperious in our pursuit to design and discover enhanced anti-viral inhibitors against this virus.  
 
A total of three compounds, ZINC18022381, ZINC33753131 and ZINC02495613 exhibited similar 
binding conformation and higher binding affinity compared to quercetin. The stability and docking 
results of the compounds in complex with NS3 were validated by performing a 200ns MD simulation 
All three systems also exhibited a higher binding affinity and binding free energy compared to the 
weaker inhibitor, quercetin; however, ZINC02495613 stands out as a more effective potential inhibitor 
of HCV NS3. The hit compounds identified in this study through application of a pharmacophore 
model, still requires biological testing in the future, for the rationalisation of their activity against HCV 
NS3. The integrated protocol presented in this study can serve as a valuable tool to significantly boost 
efforts in drug discovery and development processes. It can substantially contribute to the design of 
promising novel drugs against HCV NS3 helicase and a wide variety of other biological targets, where 
further experimental investigation of disinterred lead compounds would be beneficial.  
 
Future Perspective 
The NS3 helicase plays a pivotal role in HCV replication, however there is an evident lack of FDA 
approved inhibitors that act against the enzyme, thus the design and development of potential HCV 
helicase inhibitors should be highly prioritized. Virtual screening is a powerful tool used in 
pharmaceutical chemistry, it accelerates the discovery process whilst remaining cost-efficient. This is 
the first study, concerning HCV research, that establishes an alternative approach that may assist 
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medicinal chemists with the design and discovery of novel inhibitors against HCV helicase and 
numerous other biological targets. In the future, this study will enhance screening, design and synthesis 
of novel HCV helicase as well as other viral protein inhibitors, which can then be used in clinical trials 
evaluating treatment outcomes against HCV. 
 
Summary Points 
• The Hepatitis C virus (HCV) is rapidly becoming a global healthcare and economic burden, 
affecting more than 3% of the world’s inhabitants.  
• To date there is no available vaccine for use and the current therapeutic regimes on the market 
are ineffective due to the onset of system toxicity and drug resistance. 
• The HCV RNA helicase plays an important role in viral replication as it is responsible for 
transcription, translation and splicing of RNA. However, the immense popularity of NS3 
protease has greatly overshadowed the potential of RNA helicase as a biological target in drug 
design research. 
• Quercetin is a well-known viral inhibitor of several viruses including those in the Flavivirus 
family but exhibits instability and poor solubility within a physiological medium and is 
therefore considered a weak inhibitor. 
• Hence, we applied an in-house pharmacophore-based virtual screening protocol for 
identification of potential HCV helicase inhibitors displaying improved pharmacodynamic 
profiles that is based on highly contributing residues that bind with highest affinity to the weak 
inhibitor model.  
• Through ZINCPharmer, three lead compounds were identified and subjected to 200ns MD 
simulation. Results obtained from MM/GBSA suggested that all three compounds exhibited 
similar binding conformation and higher binding affinity in comparison to quercetin, with 
ZINC02495613 as a noticeably more effective potential inhibitor of HCV NS3 helicase.  
• This is a preliminary study that serves as a starting platform to actuate future larger-scaled 
screening of potential HCV helicase inhibitors and can be integrated in the design, discovery 
and development of antiviral drugs. 
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CHAPTER 7 
 
7.1 Conclusion 
Hepatitis C Virus (HCV) is a major causative agent of liver disease, worldwide. In the last ten years, 
basic understanding of HCV molecular virology and life cycle has advanced significantly with the use 
of HCV cell culture and replication system models coupled with enhancements in computer-aided drug 
design. This evolution in science has greatly aided rational drug design efforts, culminating in the 
generation of numerous antiviral drugs. However, current HCV therapeutics are deemed ineffective 
amongst the majority of patients due to viral genetic diversity, lack of specificity and the onset of 
adverse effects. This led to the re-emergence of covalent inhibition as a popular topic in the pharma 
industry. Scientists have taken the strategy one step further and proposed that covalent modifications of 
viral therapeutic targets through conserved cysteine amino acid residues have the potential to 
substantially contribute toward drug’s attaining viral selectivity. Selective covalent inhibition in HCV 
is a highly neglected topic in science and little is known regarding its effect and influence on the virus. 
 
This study sought to devise a criterion for the efficient implementation of selective covalent inhibition 
in HCV drug design by introducing a technical guideline or “road map” for the design and discovery of 
optimized potential selective covalent inhibitors against HCV NS3/4A protease and other viral targets. 
This study also investigated selective covalent inhibition in HCV through one of the key viral enzymes, 
NS5B RNA-dependent RNA polymerase. This mode of inhibition induced reorganization of key protein 
elements required for RNA transcription led by modifications in enzyme flexibility, correlated 
dynamics and intermolecular bonding, ultimately compromising the enzyme’s overall structural 
integrity. These insights into the mechanism of selective covalent inhibition offers significant 
understanding that will promote identification and discovery of potent, selective inhibitors against HCV 
with the potential to overcome challenges that have given way to drug resistance. 
 
This study further, shed light on HCV RNA helicase as a prospective target in drug design and proposed 
a preliminary investigation into the discovery of potential inhibitors of the helicase. The HCV helicase 
was subjected to “per-residue energy decomposition pharmacophore” virtual screening to identify 
favourable molecules that are more effective than the experimentally tested inhibitor. The results 
reported in this study will undoubtedly enhance future endeavours in designing and developing potently 
effective inhibitors against HCV. 
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Overall, this study offers a valuable insight into the mechanism of selective covalent inhibition, 
uncovering previously neglected viral target and identifying possible antiviral drugs through molecular 
modelling and computer-aided drug design.  
 
7.2 Future Perspective 
The computational approaches and parameters adopted in the present study are cost-efficient and 
powerful tools that can be effectively implemented in the process of drug design and discovery. The 
work presented in this study reveals a suitable and reliable technical guideline that may be used to 
initiate the design, discovery and development of optimized potential selective covalent HCV inhibitors.  
 
The work in this study can also facilitate further understanding of the mechanism underlying selective 
covalent inhibitors in use or development and their impact in a variety of diseases. Very little is 
understood and known about selective covalent inhibition due to focus being directed at other areas, for 
example, non-covalent inhibitors. To gain the true benefits of this mode of inhibition, the pharma 
industry must undergo a paradigm shift toward selective inhibition to advance and enhance current 
HCV therapies.  
 
To further examine the simulation validity and proposed parameters of the systems studied, the MD 
simulation can be carried out in triplicate with a longer simulation period. Performing system 
simulations in triplicate will aid in result validation as well as providing further insight and 
understanding into the mechanism of selective covalent inhibition.  
 
The potential inhibitors of the study have exhibited favourable binding energies and promising protein-
drug interactions and therefore maybe utilized as the lead compounds in anti-HCV therapy. However, 
future biological testing of these compounds is still required to verify and validate this in silico 
approach. 
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